Document:

Chloroquine Patent Sublicense Agreement

 Exhibit 4.22 
  

	*	CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THE EXHIBIT ARE MARKED BY AN *.

  
 CHLOROQUINE
PATENT SUBLICENSE AGREEMENT 
  
 This Chloroquine Patent Sublicense Agreement (Agreement) is entered into as of May
    , 2002 by and between Amersham Health A.S. (formerly Nycomed Imaging A.S.), a company organized under the laws of Norway with offices at Nycoveien 2, Post Office Box 4220, Torshov, N-0401, Oslo, Norway
(AH), and KS Avicenna (formerly INTELLIgene Expressions Inc.), a corporation organized under the laws of Canada, with offices at Edmonton Research Park, 1938-94 Street, Edmonton, Alberta, Canada T6N 1J3
(KSA). 
  
 WHEREAS, pursuant to a Patent License Agreement, L-287-00/OAH, in the form attached as Appendix A hereto, AH will be the licensee of certain patent rights from the National Institutes of Health
(NIH) or the Centers for Disease Control (CDC), or the Food and Drug Administration (FDA) hereafter singly or collectively referred to as PHS,
agencies of the United States Public Health Service within the Department of Health and Human Services (the Chloroquine Agreement), pursuant to which AH will obtain exclusive rights to certain patents. 
  
 WHEREAS, AH intends to enter into the
Chloroquine Agreement contemporaneously with AH and KSA entering into this Agreement. 
  
 WHEREAS, AH wishes to sublicense the certain patent rights licensed under the Chloroquine Agreement and KSA wishes to obtain such rights, all as set forth under the terms of this
Agreement. 
  
 NOW,
THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties agree as follows: 
  

	1.	Definitions. Except as otherwise defined in this Agreement, capitalized terms shall have the meaning set forth in this Section 1. 

  
 Earned Royalty and Earned Royalties shall have
the meaning set forth in Section 4.3 of this Agreement. 
  
 Existing Agreement means the L-006-96/0 Patent License Agreement effective February 7, 1996 between AH and PHS. 
  
 FDA means the United States Food and Drug Administration of the Department of Health and Human Services, and any successor entity.

  
 First Commercial Sale means the initial transfer
by or on behalf of KSA or its sublicensees of Licensed Products or the initial practice of a Licensed Processes by or on behalf 

  

 
of KSA or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales. 
  
 Government means the government of the United States of
America. 
  
 Licensed Fields of Use means the use of
the Licensed Patent Rights as a vascular protector during therapeutic treatment of all cancers of the central nervous system with mutated diphtheria immunotoxins. 
  
 Licensed Patent Rights means: 
  
 (a) U.S. patent applications and patents listed in Appendix B, all divisions and continuations of these
applications, all patents issuing from such applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all such patents; 
  

(b) to the extent that the following contain one or more claims directed to the invention or inventions claimed in (a) above: (i)
continuations-in-part of (a) above; (ii) all divisions and continuations of these continuations-in-part; (iii) all patents issuing from such continuations-in-part, divisions, and continuations; and (iv) any reissues, reexaminations, and extensions
of all such patents; 
  
 (c) to the extent that
the following contain one or more claims directed to the invention or inventions claimed in (a) above: all counterpart foreign applications and patents to (a) and (b) above, including those listed in Appendix B. 
  
 Licensed Patent Rights shall not include (b) or (c) above to
the extent that they contain one or more claims directed to new matter which is not the subject matter of a claim in (a) above. 
  
 Licensed Processes means processes which, in the course of being practiced would, in the absence of this Agreement, infringe one or more
claims of the Licensed Patent Rights that have not been held invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 
  
 Licensed Products means tangible materials which, in the course of manufacture, use, or sale would, in the
absence of this Agreement, infringe one or more claims of the Licensed Patent Rights that have not been held invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 
  
 Licensed Territory means the United States of America, its
commonwealths, territories and possessions. 
  
 Net Sales
means the total gross receipts for sales of Licensed Products or practice of Licensed Processes by or on behalf of KSA or its sublicensees, and from leasing, renting or otherwise making Licensed Products available to others without sale or
other dispositions, whether invoiced or not, less returns and allowances actually granted, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in
amounts customary in the trade. No deductions shall be made 

  

 2 

 
for sales or other commissions paid to individuals, whether they be with independent sales agencies or regularly employed by KSA, or sublicensees, or for the
cost of collections. 
  
 PHS Flowthrough Terms means
those provisions setting forth certain rights of PHS and obligations of KSA to PHS, as set forth in Appendix C to this Agreement. 
  
 Primary Sublicense Agreement means the Sublicense Agreement between AH and KSA dated May 19, 2000. 
  
 Research License means a nontransferable, nonexclusive license
to make and to use the Licensed Products or Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 
  

	2.	GRANT OF RIGHTS. 

  
 2.1 To Licensed Patent Rights. Subject to the terms and conditions of this Agreement, AH hereby grants and KSA accepts an exclusive license under
the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any
Licensed Processes in the Licensed Fields of Use. 
  
 2.2
Limitations. This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of AH or PHS other than Licensed Patent Rights regardless of whether such patents are dominant or
subordinate to Licensed Patent Rights. 
  
 2.3 Sublicensing
Rights. 
  
 2.3.1 Ability to
Sublicense. Upon written approval by PHS, which approval will not be unreasonably withheld, nor will a decision on approval be unduly delayed, KSA may enter into sublicensing agreements under the Licensed Patent Rights subject to the royalty
obligations set forth in Section 4 herein, provided that such Licensed Patent Rights may be sublicensed only to a party to whom KSA has granted a sublicense under the Primary Sublicense Agreement. 
  
 2.3.2 Applicability of PHS Flowthrough Terms. KSA
agrees that any sublicenses granted by it shall provide that the rights of and obligations to PHS as set forth in the PHS Flowthrough Terms of this Agreement shall be binding upon the sublicensee(s) as if it were a party to this Agreement. KSA
further agrees to attach copies of the PHS Flowthrough Terms to all such sublicense agreements. 
  
 2.3.3 Sublicensee s Rights upon Termination. Any sublicenses granted by KSA shall provide for the termination of the sublicense, or
the conversion to a license directly between such sublicensees and PHS, at the option of the sublicensee, upon termination of both this Agreement and termination of the Chloroquine Agreement. Such conversion is subject to PHS approval and contingent
upon acceptance by the sublicensee of the remaining provisions of this Agreement. 
  

 3 

 2.3.4 Copies to AH. KSA agrees to promptly forward to PHS and AH a copy of each
fully executed sublicense agreement, in all events not later than thirty (30) days after the execution of such agreement. 
  
 2.4 Reserved Government Rights: PHS Flowthrough Provisions. KSA understands and agrees that the Licensed Patent Rights are licensed to AH from PHS
under the Chloroquine Agreement, and that PHS requires that the PHS Flowthrough Provisions apply to any sublicensee of the Licensed Patent Rights. The PHS Flowthrough Provisions are incorporated herein by reference, and KSA understands and agrees
that PHS shall have the rights to bring suit directly against KSA to enforce its rights under this Agreement. 
  

	3.	DOMESTIC AND FOREIGN PATENT FILING, PROSECUTION AND
MAINTENANCE; PATENT ENFORCEMENT. 

  
 3.1 Filing. Prosecution and Maintenance. PHS has responsibility for the preparation, filing, prosecution, and maintenance of any and all patent
applications included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents as PHS deems necessary to AH who agrees to furnish such copies to KSA. Except as set forth below, as between the parties, PHS shall
have the sole right to conduct the preparation, filing, prosecution and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. 
  
 3.2 KSA Assumption of Responsibility. Upon PHS’ or AH s written request, KSA will assume the responsibility for
the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and will on an ongoing basis promptly furnish copies of all patent-related documents to PHS. In such event,
KSA will, subject to the prior approval of PHS and AH, select registered patent attorneys or patent agents to provide such services on behalf of KSA, AH and PHS. PHS and, if necessary, AH will provide appropriate powers of attorney and other
documents necessary to undertake such actions to the patent attorneys or patent agents providing such services. KSA and its attorneys or agents will consult with PHS and AH in all aspects of the preparation, filing, prosecution and maintenance of
patent applications and patents included within the Licensed Patent Rights and will provide PHS and AH sufficient opportunity to comment on any document that KSA intends to file or to cause to be filed with the relevant intellectual property or
patent office. 
  
 3.3 Assumption of Control. At any time,
PHS or AH may provide KSA with written notice that PHS or AH, respectively, wishes to assume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights. If
PHS or AH elects to assume such responsibilities, KSA agrees to cooperate fully with PHS or AH, respectively, and the respective party s attorneys and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications
or patents included in the Licensed Patent Rights and to provide PHS and AH with complete copies of any and all documents or other materials that PHS and AH deem necessary to undertake such responsibilities. KSA will be responsible for all costs
associated with transferring patent prosecution responsibilities to an attorney or agent of PHS’ or AH’s choice. 
  

 4 

 3.4 Cooperation. Each party shall promptly inform PHS and the other party as to all matters that
come to its attention that may affect the preparation, filing, prosecution, or maintenance of the Licensed Patent Rights; either party may provide comments and suggestions to the other party and PHS with respect to such preparation, filing and
maintenance. 
  
 3.5 Patent Enforcement. KSA agrees to
notify AH and PHS promptly of each infringement or possible infringement, as well as any facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which KSA becomes aware. Except as set forth herein, as between
the parties, All and PHS shall have the sole right to pursue claims of infringement of the Licensed Patent Rights against third parties; provided, however, that AH neither represents nor warrants that it will commence legal actions against third
parties infringing the Licensed Patent Rights. 
  
 3.6
Potential Enforcement by KSA. Pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code, KSA may: a) bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; b) in any such suit, engage infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for infringement of the
Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall have the first right to take such actions and shall have a continuing right to intervene in such suit. KSA shall take no action to compel the Government
either to initiate or to join in any such suit for patent infringement. KSA may request the Government to initiate or join any such suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any such suit, KSA shall
reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of such motion or other action, including my and all costs incurred by the Government in opposing any such motion or other action. Upon KSA s payment
of all costs incurred by the Government as a result of KSA s joinder motion or other action, these actions by KSA will not be considered a default in the performance of any material obligation under this Agreement. In all cases, KSA agrees to keep
PHS and AH reasonably apprised of the status and progress of any litigation. Before KSA commences an infringement action, KSA shall notify PHS and give careful consideration to the views of PHS and to any potential effects of the litigation on the
public health in deciding whether to bring suit. 
  
 3.7
Declaratory Judgment Actions. In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Licensed Patent Rights shall be brought against KSA or raised by way of counterclaim or affirmative defense in
an infringement suit brought by KSA under Section 3.6, pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code or other statutes, KSA may: a) defend the suit in its own name, at its own expense, and on its own
behalf for presumably valid claims in the Licensed Patent Rights; b) in any such suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any
claim or suit for declaratory judgment involving the Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall have the first right to take such actions and shall have a continuing right to intervene in such
suit. KSA shall take no action to compel the Government either to initiate or to join in any such declaratory judgment action. KSA may request the government to initiate or join in any such suit if necessary to avoid dismissal of the 

  

 5 

 
suit. Should the Government be made a party to any such suit by motion or any other action of KSA, KSA shall reimburse the Government for any costs,
expenses, or fees which the Government incurs as a result of such motion or other action. Upon KSA’s payment of all costs incurred by the Government as a result of KSA s joinder motion or other action, these actions by KSA will not be
considered a default in the performance of any material obligation under this Agreement. If KSA elects not to defend against such declaratory judgment action, PHS, at its option, may do so at its own expense. In all cases, KSA agrees to keep PHS and
AH reasonably apprised of the status and progress of any litigation. Before KSA commences an infringement action, KSA shall notify PHS and AH and give careful consideration to the views of PHS and AH and to any potential effects of the litigation on
the public health in deciding whether to bring suit. 
  
 3.8 AH
Cooperation in KSA Enforcement Actions. AH shall cooperate fully with KSA in connection with an infringement action initiated under Sections 3.6 and 3.7. AH agrees promptly to provide access to all necessary documents and to render reasonable
assistance in response to a request by KSA at KSA’s expense. 
  

	4.	PAYMENTS. 

  
 4.1. Benchmark Royalty Payments. KSA agrees to pay AH the nonrefundable Benchmark Royalties as set forth in Appendix D. KSA expressly acknowledges
and agrees that none of the Benchmark Payments set forth in this Section shall be credited against any Earned Royalties described in Section 4.3 below or against any royalty obligations under the Primary Sublicense Agreement. 
  
 4.2 License Issue Royalty Payments. KSA agrees to pay AH a
noncreditable, nonrefundable license issue royalty as set forth in. Appendix D within thirty (30) days from the date that this Agreement becomes effective. KSA expressly acknowledges and agrees that none of the License Issue Payments set forth in
this Section shall be credited against any Earned Royalties described in Section 4.3 below or against any royalty obligations under the Primary Sublicense Agreement. 
  
 4.3 Earned Royalty. KSA agrees to pay AH the earned royalties as set forth in Appendix D (hereinafter referred to as
the Earned Royalty or Earned Royalties). 
  
 4.4 Sublicense Royalty. KSA agrees to pay AH a noncreditable, nonrefundable sublicense issue royalty as set forth in Appendix D within thirty (30) days from the date such sublicense becomes effective.

  
 4.5 Minimum Annual Royalty. KSA agrees to pay AH a
nonrefundable minimum annual royalty as set forth in Appendix D. The minimum annual royalty is due and payable on January 1 of each calendar year and may be credited against any Earned Royalties due for sales made in that year. The minimum annual
royalty due for the first calendar year of this Agreement may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1. 
  

 6 

 4.6 Patent Expenses. With regard to expenses associated with the preparation, filing, prosecution,
and maintenance of AH patent applications and patents included within the Licensed Patent Rights incurred by PHS and AH prior to the effective date of this Agreement, KSA will pay to AH, as an additional royalty, within sixty (60) days of AH’s
submission of a statement and request for payment to KSA, an amount equivalent to such patent expenses previously incurred by PHS and AH. KSA agrees to pay AH annually, within sixty (60) days of AH submission of a statement and request for payment,
an amount equivalent to all reasonable expenses incurred by PHS after the Effective Date in the preparation, filing, prosecution, and maintenance of the Licensed Patent Rights. 
  
 4.7 A patent or patent application licensed under this Agreement will cease to fall within the Licensed Patent Rights for
the purpose of computing earned royalty payments in any given country on the earliest of the dates that the claim has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or
administrative agency. 
  
 4.8 Except as specifically set forth
herein, no multiple royalties will be payable because any Licensed Product(s) or Licensed Process(es) are covered by more than one of the Licensed Patent Rights. 
  

	4.9	ADJUSTMENTS TO ROYALTY. 

  

4.9.1 Adjustments Regarding Expenses in KSA Enforcement Actions. In any action under Sections 3.6 or 3.7, the expenses including
costs, fees, attorney fees, and disbursements, will be paid by KSA. Up to fifty percent (50.0%) of such expenses may be credited against the royalties payable to AH under Section 4.3 of this Agreement under the Licensed Patent Rights in the country
in which such suit is filed. In the event that fifty percent (50.0%) of such expenses exceed the amount of royalties payable by KSA in any calendar year, the expenses in excess may be carried over as a credit on the same basis into succeeding
calendar years. A credit against litigation expenses, however, may not reduce royalties due in any calendar year to less than the Minimum Royalties of Section 4.5 of this Agreement. Any recovery made by KSA, through court judgment or settlement,
first shall be applied to reimburse AH for royalties withheld as a credit against litigation expenses and then to reimburse KSA for its litigation expenses. Any remaining recoveries shall be shared equally by KSA and AH. 
  
 4.9.2 Commercialization License Credit. Should PHS
grant a commercialization license to a party other than AH or KSA for rights not granted under this Agreement, e.g. for the use of chloroquine or other endosome pH-raising agents in conjunction with Pseudomonas exotoxin mutants, AH agrees to
grant KSA a credit for the appropriate share (for example, should one additional license be granted, KSA shall be granted a credit of fifty percent (50.0%) of any previously reimbursed patent expenses, due under Section 4.6 of this Agreement, and
then shall be expected to reimburse AH fifty percent (50.0%) of any future patent expenses, due under Section 4.6 of this Agreement) of the related patent expenses. This proportional credit shall be taken against earned royalties due on Net Sales.

  
 4.10 Payment Terms. All payments, if any, under this
Agreement shall be made in U.S. dollars. For conversion of foreign currency to U.S. dollars, the conversion rate shall be 

  

 7 

 
the rate quoted in The Wall Street Journal on the day that the payment is due. All checks and bank drafts shall be drawn on United States banks and shall be
payable to Amersham Health, A.S. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by KSA. All payments due under this Agreement shall be nailed to the following
address: Nycoveien 2, Post Office Box 4220, Torshov, N-0401, Oslo, Norway, Attention: Tim Martin. The Royalty report required by Section 5.3 of this Agreement shall accompany each such payment and a copy of such report shall also be mailed to AH at
its address for notices. All amounts payable under this Agreement are exclusive of all sales, use, value-added, withholding, and other taxes and duties. KSA will pay all taxes and duties assessed in connection with this Agreement and its performance
by any authority within or outside of the U.S., except for taxes payable on AH s net income. AH will be promptly reimbursed by KSA for any and all taxes and duties that AH may be required to pay in connection with this Agreement or its performance.
AH shall cooperate and assist KSA with any steps that may be required to minimize the payment of taxes and duties under this section or recover part or all of any taxes or duties paid under this Section. All amounts which remain unpaid after s due
date shall be subject to interest charges at the rate of one percent (1%) per month, or the highest rate permitted by law, whichever is lower. 
  

	5.	RECORDS AND AUDITS; REPORTS. 

  
 5.1 Recordkeeping and Audits. KSA agrees to keep accurate and correct records of Licensed Products made, used, or
sold and Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties, if any, due AH. Such records shall be retained for at least five (5) years following a given reporting period. They shall be available
during normal business hours at KSA s premises for inspection at the expense of AH by an accountant or other designated auditor selected by AH for the sole purpose of verifying reports and payments hereunder. The accountant or auditor shall only
disclose to AH information relating to the accuracy of reports and payments made under this Agreement. If an inspection shows an under reporting or underpayment in excess of five (5%) percent for any twelve (12) month period, then KSA shall pay the
unreported Royalties, including any late charges as required by Section 4.2 of this Agreement. All payments required under this Section shall be due within thirty (30) days of the date AH provides KSA notice of the payment due. 
  
 5.2 Compulsory Audit. KSA agrees to have an audit of sales and
royalties conducted by an independent auditor at least every two (2) years if Net Sales of the Licensed Product or Licensed Processes are over two million dollars (US$2,000,000.00). The audit will address, at a minimum, the amount of gross sales by
or on behalf of KSA during the audit period, terms of the license as to percentage or fixed royalty to be remitted to AH, the amount of royalty funds owed to AH under this Agreement, and whether the royalty amount owed has been paid to AH and is
reflected in the records of the KSA. The audit will also indicate the PHS license number, product, and the time period being audited. A report certified by the auditor will be submitted promptly by the auditor directly to AH and PHS on completion.
KSA will pay for the entire cost of the audit. 
  
 5.3 Royalty
Report. KSA shall submit to AH within thirty (30) days after each calendar half-year ending June 30 and December 31 a royalty report setting forth for the 

  

 8 

 
preceding half-year period the amount of the ‘Licensed Products sold or Licensed Processes practiced by or on behalf of KSA in each country within the
Licensed Territory, the Net Sales, and the amount of Royalties accordingly due. With each such royalty report, KSA shall “submit payment of the Earned Royalties due. If no earned royalties or payments are due to AH for any reporting period, the
written report shall so state. The royalty report shall be certified as correct by an authorized officer of KSA and will include a detailed listing of all deductions made pursuant to the definition of Net Sales under Section 1 of this Agreement to
determine royalties due. 
  
 5.4 Additional Reports. AH and
KSA acknowledge that KSA is obligated to submit certain written reports to PHS and AH under the Primary Sublicense Agreement. In the event that PHS requires that any additional reports be submitted under the Chloroquine Agreement, KSA shall provide
such reports in a timely fashion upon request from either PHS or AH. 
  

	6.	PERFORMANCE BY KSA. 

  
 6.1 Efforts to Commercialize. KSA shall use its reasonable best efforts to introduce the Licensed Products into the commercial market or apply the
Licensed Processes to commercial use as soon as practicable. Reasonable best efforts for the purpose of this provision shall include, but not be limited to, adherence to the Commercial Development Plan and performance of the Benchmarks attached
hereto as Appendices E and F, respectively. The efforts of a sublicensee shall be considered the efforts of KSA. 
  
 6.2 Efforts to Make Available to Public. Upon First Commercial Sale, until the expiration of this Agreement, KSA shall use reasonable best efforts
to keep Licensed Products and Licensed Processes reasonably accessible to the public in the Licensed Territory. 
  

	7.	WARRANTY AND DISCLAIMERS; INDEMNIFICATION BY KSA; LIMITATION
OF LIABILITY. 

  
 7.1 Due Diligence by KSA. Except as specifically stated herein, AH makes no representations or warranties as to any aspect of the Licensed Products or Licensed Processes. AH does not make any representation or warranty as to the
business prospects of the Licensed Products or Licensed Processes. KSA acknowledges and agrees that (a) KSA has conducted its own review and analysis, as it deemed necessary and appropriate, of the business prospects of the Licensed Products or
Licensed Processes and is not relying on any representations or warranties from AH as to the business prospects; and (b) in making the decision to license. the Licensed Patent Rights, KSA has relied solely on independent investigations made by KSA
or KSA s financial and legal advisors, has had the opportunity to review information and have questions answered by management and employees of AH, and deems such information received and reviewed adequate to evaluate the merits and risks of the
business prospects of the Licensed Products and Licensed Processes. 
  

 9 

 7.2 Mutual Authority. Each party represents and warrants to the other that: 
  
 7.2.1 Corporate Power. It is duly organized and
validly existing under the laws of its state or country of incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
  
 7.2.2 Due Authorization. It is duly authorized to execute and deliver this Agreement and to perform
its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action. 
  
 7.2.3 Binding Agreement. This Agreement is legally binding upon it and enforceable in accordance with
its terms. The execution, delivery and performance of this Agreement by it to the best of its knowledge does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor
violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 
  
 7.3 Disclaimers. 
  
 7.3.1 No Warranty of Scope, Infringement, or Approvals. AH does not represent or warrant the validity of the Licensed Patent Rights
and makes no representations or warranties whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third
parties, or that the Licensed Products or Licensed Processes are acceptable for filing with the FDA or whether any authorization or approval will be obtained from the FDA. 
  
 7.3.2 General Disclaimer. THE LICENSED PATENT RIGHTS ARE LICENSED TO KSA ON AN AS IS BASIS, AND AH
MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR OTHERWISE. 
  
 7.4 Indemnification by KSA. KSA shall indemnify and hold AH and PHS, its affiliates, officers, directors, employees,
students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of (a) the
use by or on behalf of KSA, its sublicensees, directors, employees, or third parties of any Licensed Patent Rights, or (b) the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes, or other products or processes
developed in connection with or arising out of the Licensed Patent Rights. KSA agrees to maintain a liability insurance program consistent with sound business practice, with a minimum coverage of Ten Million Dollars (US$10,000,000), provided that
the obligation to place liability insurance shall not become applicable until thirty (30) days prior to the first application for Institutional Review Board (IRB) approval for Clinical Trials 
  
 7.5 Indemnification by AH. AH shall indemnify and hold KSA, its
affiliates, officers, directors, employees, agents, and consultants harmless from and against all liability, demands, 

  

 10 

 
damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out claims
brought by or for individuals who were administered a product embodying Licensed Products or using Licensed processes that were created via AH’s development efforts prior to the Effective Date. 
  
 7.6 Exclusion of Damages and Limitations of Liability. IN NO EVENT
WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY LOST REVENUES OR PROFITS, COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, OR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING
NEGLIGENCE), PRODUCT LIABILITY, OR OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. EXCEPT FOR THE INDEMNIFICATION UNDER SECTION 7.5 ABOVE UNDER NO CIRCUMSTANCES SHALL AH BE LIABLE TO KSA FOR ANY AMOUNT
GREATER THAN THE AMOUNT PAID BY KSA TO AH UNDER THE TERMS OF THIS AGREEMENT LESS ANY AMOUNTS PAID BY AH TO PHS. 
  

	8.	TERM AND TERMINATION. 

  
 8.1 Term. This Agreement shall come into force and effect on the date on which AH and PHS enter into the Chloroquine Agreement in the form attached
as Appendix A to this Agreement (the Effective Date) and, unless sooner terminated by the parties as otherwise provided, shall continue in effect until the last to expire of the Licensed Patent Rights (Term). 
  
 8.2 Events of Termination. Either party (or the specific party named
below, as applicable) will have the right to terminate this Agreement if or upon: 
  
 8.2.1 Breach. The other party breaches any material term or condition of this Agreement and fails to cure such breach within sixty
(60) days after written notice, which shall include without limitation any failure of KSA to meet the Benchmarks set forth on Attachment F hereto; 
  
 8.2.2 Termination of Other Agreements. The termination of the Chloroquine Agreement or, prior to the expiration thereof, the
termination of the Existing Agreement or the termination of the Primary Sublicense Agreement; 
  
 8.2.3 Voluntary Bankruptcy. The other party becomes the subject of a voluntary petition in bankruptcy or any voluntary proceeding
relating to insolvency, receivership, liquidation, or composition for the benefit of creditors; 
  
 8.2.4 Involuntary Bankruptcy. The other party becomes the subject of an involuntary petition in bankruptcy or any involuntary
proceeding relating to insolvency, receivership, liquidation, or composition for the benefit of creditors, if such petition or proceeding is not dismissed within sixty (60) days of filing; 
  
 8.2.5 Government Restrictions. The Licensed Products
and Licensed Processes may no longer be used, sold or otherwise distributed in the Licensed Territory due to government laws or regulations prevailing in the Licensed Territory; 
  

 11 

 8.2.6 Termination by PHS. This Agreement, and/or AH s license to the Licensed
Patent Rights from PHS under the Chloroquine Agreement, is terminated as a result of PHS reserved rights under either agreement; or 
  
 8.2.7 Nonuse by KSA. KSA determines that it does not wish to initiate or continue commercialization or other use of the Licensed
Patent Rights under this Agreement, and provides AH with at least ninety (90) days prior written notice of its intent to terminate this Agreement. 
  
 8.3 Rights upon Termination. Upon any termination of this Agreement for any reason: 
  
 8.3.1 Not later than thirty (30) days following such termination, each party shall return to the other any
and all Confidential Information of the other party in its possession or control. 
  
 8.3.2 In the event that AH terminates this Agreement, KSA shall promptly deliver to AH all KSA Know-How, and KSA hereby grants to AH a
perpetual, nonexclusive license (with the right to sublicense) to use KSA Know-How as needed for AH and its sublicensees to fully exercise the Licensed Patent Rights. For purposes of this Agreement, KSA Know-How means all inventions,
discoveries, trade secrets, information, experience, data, formulas, procedures and results, and improvements thereon, whether or not patentable or patented, which are created or obtained by KSA during the term of this Agreement in connection with
its activities related to the Licensed Patent Rights, and which may be necessary or useful in the manufacture, use or sale of any Licensed Products or Licensed Processes. 
  
 8.3.3 KSA shall have the right to convert its license to the Licensed Patent Rights under this Agreement
into a license directly from PHS, upon PHS approval of same and KSA s consent to applicable provisions required by PHS. 
  

	9.	CONFIDENTIALITY. 

  
 9.1 Confidential Information. “Confidential Information” means: (a)°any business or technical information of KSA or AH,
including but not limited to any information relating to KSA’s or AH’s product plans, designs, costs, finances, marketing plans, business opportunities, personnel, research, pending patent applications, development or know-how; and
(b)°the terms and conditions of this Agreement. 
  
 9.2
Exceptions. Confidential Information shall, not include information that: (a)°is in or enters the public domain without breach of this Agreement through no fault of the receiving party; (b)°the receiving party was demonstrably in
possession of prior to first receiving it from the disclosing party; (c)°the receiving party can demonstrate was developed by the receiving party independently and without use of or reference to the disclosing party’s Confidential
Information; or (d) the receiving party receives from a third party without restriction on disclosure and without breach of a nondisclosure obligation. 
  

 12 

 9.3 Obligations. Each party will maintain the Confidential Information of the other party in
strict confidence and will exercise due care with respect to the handling and protection of such Confidential Information, consistent with its own policies concerning protection of its own Confidential Information of like importance. Each party will
use the Confidential Information of the other party only as expressly permitted herein, and will disclose such Confidential Information only to its employees and consultants as is reasonably required in connection with the exercise of its rights and
obligations under this Agreement (and only subject to binding use and disclosure restrictions at least as protective as those set forth herein executed in writing by such employees and consultants). KSA expressly understands and agrees that AH shall
have the right to disclose Confidential Information of KSA to PHS solely to the degree required by AH s disclosure obligations under the Chloroquine Agreement. However, each party may disclose Confidential Information of the other party pursuant to
the order or requirement of a court, administrative agency, or other governmental body, provided that the receiving party gives reasonable notice to the other party to contest such order or requirement. Any such disclosure by the receiving party of
the Confidential Information of the disclosing party, will, in no way, be deemed to change, affect or diminish the confidential and proprietary status of such Confidential Information. 
  
 9.4 InjunctiveoRelief. Each party acknowledges that improper use or disclosure of the Confidential Information
of the other party would cause substantial harm to the other party that could not be remedied by the payment of damages alone. Accordingly, each party will be entitled to preliminary and permanent injunctive relief and other equitable relief for any
breach of this Section 9. 
  

	10.	PHS CONSENTS. PHS hereby agrees as follows: 

  
 10.1 Approval of Sublicense. PHS has, in accordance with Article 4 of the Chloroquine Agreement, approved this Agreement. 
  
 10.2 Communications and Approvals. KSA shall have the right to report
on AH s behalf to, and to seek approvals on AH s behalf from, PHS as contemplated under Sections 2.3.1, 2.3.3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, .8, 5.1, 5.2, 5.3, and 5.4 of this Agreement. Any reports or communications contemplated under those
Sections shall be treated by PHS as reports or communications from AH. Any approvals given by PHS under the above referenced Sections shall be deemed an approval by AH under this Agreement. 
  

	11.	GENERAL PROVISIONS. 

  
 11.1 Waiver. Neither party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either party to
assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver or that right by either party or excuse a similar subsequent failure to perform any such term or condition by this other
party. 
  
 11.2 Entire Agreement. This Agreement
constitutes entire agreement between the Parties relating to the subject matter of the Licensed Patent Rights and all prior negotiations, 

  

 13 

 
representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this Agreement. 
  
 11.3 Severability. The provisions of this Agreement are severable, and
in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such determination shall not in any way affect the validity or enforceability of the remaining provisions of this
Agreement. 
  
 11.4 Modification. If either party desires a
modification to this Agreement, the Parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in good faith to determine the desirability of such modification. No modification will be effective until
a written amendment is signed by the signatories to this Agreement. 
  
 11.5 Governing Law; Dispute Resolution. The construction, validity, performance, and effect of this Agreement shall be governed by the laws of New Jersey and of the United States, excepting those portions thereof relating to
conflicts of law. All disputes arising under this Agreement shall be resolved solely in the federal or state courts situated in New Jersey and both parties hereby submit to the personal jurisdiction thereof. 
  
 11.6 Notices. All notices required or permitted by this Agreement
shall be given by prepaid, first class, registered or certified mail properly addressed to the other party at the address designated on the first page of this Agreement, or to such other address as may be designated in writing by such other party,
and shall be effective as of the date of the postmark of such notice. 
  
 11.7 Assignment. This Agreement shall not be assigned by KSA except (a) with the prior written consent of AH, such consent to be reasonably given; or (b) as part of a sale or transfer of substantially the entire business of KSA
relating to operations which concern this Agreement. KSA shall notify AH within ten (10) days of any assignment of this Agreement by KSA. 
  
 11.8 Use of Items from AH and its Licensors. KSA agrees in its use of any AH supplied items to comply with all applicable statutes, regulations,
and guidelines, including Public Health Service and National Institutes of Health Regulations and guidelines. KSA agrees not to use the materials for research involving human subjects or clinical trials in the United States without complying with 21
CFR Part 50 and 45 CFR Part 46. KSA agrees not to use the items for research involving human subjects or clinical trials outside of the United States without notifying AH, in writing, of such research or trials and complying with the applicable
regulations of the appropriate national control authorities. Written notification to AH of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of such
research or trials. 
  
 11.9 Export Control. KSA
acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory
prototypes, biological material, and other commodities. The transfer of such items may require a license from the cognizant agency of the U.S. Government or written assurances by KSA that it 

  

 14 

 
shall not export such items to certain foreign countries without prior approval of such agency. AH neither represents nor warrants that a license is or is
not required or that, if required, it shall be issued. 
  
 11.10
Marking of Licensed Products. KSA agrees to mark the Licensed Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate Patent Pending status. All Licensed Products manufactured
in, shipped to, or sold in other countries shall be marked in such a manner as to preserve AH s or its licensor s patent rights in such countries. 
  
 11.11 Survival. Sections 2.3.3, 2.4, 4, 7, 8, 9, 10, and 11 of this Agreement shall survive termination of this Agreement. 
  
 11.12 Counterparts. This Agreement may be executed in multiple
counterparts, each of which when so executed, shall be deemed to be an original copy hereof, and all such counterparts together shall constitute one single agreement. 
  
 [Remainder of Page Left Blank] 
  

 15 

 [Signature Page to Sublicense Agreement] 
  
 IN WITNESS
WHEREOF, the parties have caused this Agreement to be signed by their duly authorized representatives. 
  

									
	KS AVICENNA, INC.	 	 	 	AMERSHAM HEALTH A.S.
					
	By:	 	 /s/ Fahar Merchant
	 	 	 	By:	 	 /s/ Ase Aulie Michelet

	 Name:
	 	 Fahar Merchant
	 	 	 	 Name:
	 	 Ase Aulie Michelet

	 Title:
	 	 Chief Technology Officer
	 	 	 	 Title:
	 	 President Amersham Health A.S

  

 16 

 APPENDIX A 
 CHLOROQUINE AGREEMENT 
  

 17 

 APPENDIX B 
 PATENTS OR PATENT APPLICATIONS 
  
 USPA, S/N 60/212,909, [DHHS Ref. No.: E-288-99/0] entitled, Methods of Protecting Vasculature From Damage by Diphtheria Toxin- and Pseudomonas Toxin-Based Immunotoxins
During Therapy, filed on June 20, 2000. 
  
 USPA, S/N 09/884,695, [DHHS Ref.
E-288-99/1], entitled, Methods of Protecting Vasculature From Damage by Diphtheria Toxin- and Pseudomonas Toxin-Based Immunotoxins During Therapy, which was filed on June 19, 2001. 
  

 18 

 APPENDIX C 
 PHS FLOWTHROUGH TERMS 
  
 1. Government Reserved Rights. 
  
 1.1 Reserved License Rights. KSA agrees that PHS has reserved on behalf of the Government of the United States of America (the
Government) an irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of
any foreign government or international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory. 
  
 1.2 Cooperative Research and Development Agreement Rights. In the event that Licensed Patent Rights are Subject Inventions made under a Cooperative
Research and Development Agreement (CRADA), KSA grants to the Government, pursuant to 15 U.S.C. /3710a(b)(l)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice Licensed Patent Rights or have Licensed Patent Rights
practiced throughout the world by or on behalf of the Government. In the exercise of such license, the Government will not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning
of 5 U.S.C. /552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale, KSA agrees to provide PHS reasonable quantities of Licensed Products or materials made through the
Licensed Processes for PHS research use. PHS shall assume liability for its research use of the Licensed Products. 
  
 2. Manufacture in United States. KSA agrees that products used or sold in the United States embodying Licensed Products or produced through use of Licensed
Processes will be manufactured substantially in the United States, unless a written waiver is obtained in advance from PHS. PHS agrees that the waiver KSA requested and received for the Existing Agreement (see Attachment One) shall also apply to
this Agreement. 
  
 3. Future Cooperative Research and Development
Agreements. KSA acknowledges that PHS may enter not future Cooperative Research and Development Agreements (CRADAs) under the Federal Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. KSA agrees not to
unreasonably deny requests for a research License from such future collaborators with PHS when acquiring such rights is necessary in order to make a Cooperative Research and Development Agreement (CRADA) project feasible. KSA may request an
opportunity to join as a party to the proposed Cooperative Research and Development Agreement (CRADA). 
  
 4. Research Licenses. 
  
 4.1 Grant of Research License. In addition to the reserved license of Paragraph 3 above in this Appendix C, PHS reserves the right to grant nonexclusive Research Licenses directly or to require KSA to grant nonexclusive Research
Licenses on reasonable terms. The purpose of this Research License is to encourage basic research, whether conducted at an academic or corporate facility, but in no event shall the Research License be used for any 

  

 
commercial purpose. Additionally and in order to safeguard the Licensed Patent Rights, however, PHS will consult with KSA before granting to commercial
entities a Research License or providing to them research samples of materials made through the Licensed Processes. 
  
 4.2 Required Research Licenses. In exceptional circumstances, and in the event that Licensed Patent Rights are Subject Inventions made under a
Cooperative Research and Development Agreement (CRADA), the government, pursuant to 15 U.S.C. /3710a(b)(1)(B), retains the right to require KSA to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use
Licensed Patent Rights in KSA’s field of use on terms that are reasonable under the circumstances; or if KSA fails to grant such a license, the Government retains the right to grant the license itself. The exercise of such rights by the
Government will only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by KSA; (ii) the action is necessary to meet requirements for
public use specified by Federal regulations, and such requirements are not reasonably satisfied by the KSA; or (iii) KSA has failed to comply with an agreement containing provisions described in 15 U.S.C. /3710a(c)(4)(B). The determination made by
the Government under this Article is subject to administrative appeal and judicial review under 35 U.S.C. /203(2). 
  
 5. Recordkeeping and Audits. KSA agrees to keep accurate and correct records of Licensed Products made, used, or sold and Licensed Processes practiced under
this Agreement appropriate to determine the amount of royalties due AH. Such records shall be retained for at least five (5) years following a given reporting periods. They shall be available during normal business hours at KSA s premises for
inspection at the expense of PHS by an accountant or other designated auditor selected by PHS for the sole purpose of verifying reports and payments hereunder. The accountant or auditor shall only disclose to PHS information relating to the accuracy
of reports and payments made under this Agreement. If an inspection shows an under reporting or underpayment in excess of five (5%) percent for any twelve (12) month period, then KSA shall pays the unreported Royalties, including any late charges as
required by Section 4.5 of this Agreement. All payments required under this Section shall be due within thirty (30) days of the date PHS provides KSA notice of the payment due. 
  
 6. Efforts to Commercialize. KSA shall use its reasonable best efforts to introduce the Licensed Products into the commercial
market or apply the Licensed Processes to commercial use as soon as practicable. Reasonable best efforts for the purpose of this provision shall include, but not be limited to, adherence to the Commercial Development Plan. The efforts of a
sublicensee shall be considered the efforts of KSA. 
  
 7. Efforts to Make
Available to Public. Upon First Commercial Sale, until the expiration of this Agreement, KSA shall use the reasonable best efforts to keep Licensed Products and Licensed Processes reasonably accessible to the public in the Licensed
Territory. 
  
 8. Indemnification by KSA. KSA will indemnify, as of
the effective date of this Agreement, and hold PHS and AH, their employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal
injury, illness, or property damage in connection with or arising out of: a) the use by or on behalf of KSA, its sublicensees, directors, employees, or third parties of 

  

 
any Licensed Patent Rights; or b) the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or materials by KSA, or other
products or processes developed in connection with or arising out of the Licensed Patent Rights. KSA agrees to maintain a liability insurance program consistent with sound business practice. 
  
 9. Required Sublicenses. When the public health and safety so require, and
after written notice to KSA providing KSA a sixty (60) day opportunity to respond, PHS will have the right to require KSA to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent
Rights, unless KSA can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. PHS will not require the granting of a sublicense
unless the responsible applicant has first negotiated in good faith with KSA. 
  
 10. Termination. PHS reserves the right according to 35 U.S.C. /209(f)(4) to terminate or modify this Agreement if it is determined that such action is necessary to meet requirements for public use specified by federal
regulations issued after the date of the license and such requirements are not reasonably satisfied by KSA. 
  
 11. Appeal of Termination. Within thirty (30) days of receipt of written notice of PHS unilateral decision to modify or terminate this Agreement, KSA may, consistent with the provisions of 37 CFR Part
404.11, appeal the decision by written submission to the designated PHS official. The decision of the designated PHS official will be the final agency decision. KSA may thereafter exercise any and all administrative or judicial remedies that may be
available. 
  
 12. Final Report. Within ninety (90) days of
expiration or termination of this Agreement, a final report will be submitted by KSA to AH and PHS. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expense, due
to AH will become immediately due and payable upon termination or expiration. If terminated under Section 8 of the Agreement, sublicensees may elect to convert their sublicenses to direct licenses with PHS pursuant to Paragraph 4.03 of the
Chloroquine License. Unless otherwise specifically provided for under this Agreement, upon termination or expiration of this Agreement, KSA will return all Licensed Product(s) or other materials included within the Licensed Patent Rights to AH or
provide AH with certification of the destruction thereof. 
  

 ATTACHMENT ONE TO APPENDIX C 
  
 Monday, May 15, 2000 
  
 Mr. Stephen M. Wage, Director 
 Business
Development 
 Nycomed Amersham Imaging, Inc. 
 101 Carnegie
Center 
 Princeton, New Jersey 08450-6231 
  
 Dear Stephen: 
  

	 	Re:	“Waiver” of United States Manufacturing Requirement for the production of a diptheria immunotoxin based therapeutic drug referred to as HN66000 (-Tf-CRM107) (OTT Ref.
No.: L-006-96/0) and (OTT Ref. No.: L-007-96/0) 

  
 I am pleased to
inform you that, pursuant to your Sublicense with INTELLIgene Expressions, Inc (Edmonton, Alberta, Canada), NIH’s Office of Technology Transfer has granted Nycomed Imaging A.S., a waiver of the U.S. manufacturing requirement for the production
of a diptheria immunotoxin based therapeutic drug referred to as HN66000 (Tf-CRM107) for the treatment of human cancers of the central nervous system and/or the head and neck (e.g., anaplastic astrocytoma and glioblastoma multiforme) which is
licensed to Nycomed Imaging A.S. under the terms of OTT Ref. No.: L-006-96/0 and pursuant to a “Patent License Agreement -Nonexclusive” for the development, use, and/or sale of an intratumoral implanted catheter and pump and/or drug
delivery system employing the technology and methods of U.S. Patent 5,720,720, entitled: “Convection-Enhanced Drug Delivery” for use in the intratumoral delivery of the HN66000 (Tf-CRM107) drug - OTT Ref. No.: L-007-96/0. Note, these
waivers may be rescinded, if the terms of the sublicense with INTELLIgene Expression, Inc. or the terms of the L-006-96/0 license and/or the terms of the L-007-96/0 license are terminated for any reason. Also, these waivers are granted specifically
to Nycomed Imaging A.S. pursuant to the sublicense to INTELLIgene Expressions, Inc., and these waivers can not be included in any sublicense to another company or party without NIH’s Office of Technology Transfer written permission. 

 

 The Office of Technology Transfer is looking forward to having the terms of the sublicense agreement associated with this
waiver completed and having the HR66000/Tf-CRM107 drug made available for the public good. Thank you for your interest in developing the technology from the U.S. Public Health Service. 
  

	
	 Sincerely,

	
	 
	 Jack Spiegel, Ph.D., Director
 Division of Technology Development and
 Transfer
 Office of Technology Transfer
 National Institutes of Health

  

	cc:	INTELLIgene Expression, Inc. (Edmonton, Alberta, Canada) 

  

 APPENDIX D 
 ROYALTIES 
  
 1. License Issue Royalty. KSA agrees to pay to AH a noncreditable, nonrefundable License Issue Royalty in the amount of * . 
  
 2. Minimum Annual Royalty. KSA agrees to pay AH a minimum annual royalty as follows: 
  
 2.1 Zero Dollars (US$0.0) as long as the Existing Agreement is in effect and KSA is current with all its obligations under
the Primary Sublicense Agreement; or 
  
 2.2 * should the Existing
Agreement or the Primary Sublicense Agreement be terminated or KSA does not cure, within ninety (90) days of a written notice from AH, a material breach of the obligations provided by the terms of the Primary Sublicense Agreement. 
  
 3. Earned Royalty. KSA agrees to pay AH earned royalties on Net Sales by or on behalf
of KSA and its sublicensees as follows: 
  
 3.1 * of Net Sales as
defined in the Primary Sublicense Agreement; 
  
 3.1.1 The parties agree and acknowledge that pursuant to Section 2.6.3 of the Primary Sublicense Agreement, the license granted pursuant to Article 2 of this Agreement is granted for no additional payments beyond those set forth in the
Primary Sublicense Agreement and those set forth in this Appendix D, provided that KSA shall remain responsible for the payment of royalties in accordance with the Primary Sublicense Agreement such that any Net Sales, as defined herein, have been
accounted for under the Primary Sublicense Agreement and applicable royalties have been paid to AH with respect to such Net Sales. In the event that such royalties are not paid under the Primary Sublicense Agreement, KSA shall pay AH a royalty based
on Net Sales, as defined herein and in the Primary Sublicense Agreement, at the same rates and amounts and on the same terms and conditions as specified in Section 4 of the Primary Sublicense Agreement. In addition and because the sales of Licensed
Products or practice of Licensed Processes, each as defined herein, shall include a combination of Licensed Products and/or Licensed Processes, each as defined in the Primary Sublicense Agreement, and a suitable endosome pH-raising agent, as defined
by the Licensed Patent Rights (for example, chloroquine) KSA shall pay an additional one percent (I%) royalty finder this Agreement for Net Sales of Licensed Products or practice of Licensed Processes as these terms are defined in the Primary
Sublicense Agreement and this Agreement, namely, mutated diphtheria immunotoxins, for the indicated Licensed Field of Use and in the Licensed Territory. Notwithstanding anything in this Section 3.1.1 of Appendix D to the contrary, consistent with
Section 4.4(f) of the Primary Sublicense Agreement the additional royalty rate owed under this Agreement shall be reduced to * while the Primary Sublicense Agreement is in effect. Therefore, while the Primary Sublicense Agreement and this Agreement
are in effect, KSA shall pay AH the royalty rate set forth in the Primary Sublicense Agreement on Net Sales of the Licensed Products or practice of Licensed Processes as those terms are defined under the Primary Sublicense Agreement and this
Agreement, specifically, the applicable royalty rate under the Primary Sublicense Agreement and * under this Agreement. 
  

 3.2 Notwithstanding the terms of Section 3.1 of this Appendix D, after expiration of the last to expire
of the Licensed Patent Rights, as defined in the Primary Sublicense Agreement, and until expiration of the last to expire of the Licensed Patent Rights, as defined herein, KSA shall pay AH a royalty of * of Net Sales as defined in this Agreement
and, without duplication, Net Sales as defined in the Primary Sublicense Agreement without regard to the term of any patent) in combination with Net Sales as defined in this Agreement. KSA further agrees that the total earned royalties due to AH can
rise to a total of * should the provisions of the related non-exclusive patent licenses, the Manufacturing Patent License Agreement and Drug Delivery Patent Sublicense Agreement between the parties and dated on even date herewith, be in effect. In
such a case, * under this Agreement, * under such Manufacturing Patent License Agreement and * under Drug Delivery Patent Sublicense Agreement. 
  
 4. Benchmark Royalties. KSA agrees to pay AH Benchmark Royalties as follows: 
  
 4.1 * — upon filing of the first application for regulatory approval to conduct a clinical trial in humans anywhere in
the Licensed Territory utilizing and/or directed to Licensed Product(s) and/or Licensed Process(es); 
  
 4.2 * — upon the completion of the first Phase II Clinical Trials in humans anywhere in the Licensed Territory utilizing and/or directed to Licensed
Product(s) and/or Licensed Process(es) anywhere in the Licensed Territory; 
  
 4.3 * — upon the completion of the first Phase III Clinical Trials in humans anywhere in the Licensed Territory utilizing and/or directed to Licensed Product(s) and/or Licensed Process(es); and 
  
 4.4 * — upon marketing approval anywhere in the Licensed Territory
utilizing and/or directed to Licensed Product(s) and/or Licensed Process(es). 
  
 5. Sublicense Royalties. In addition to the royalties set forth in this Appendix D, KSA agrees to pay AH additional sublicensing royalties of * of any consideration, except earned royalties on Net Sales under Section 3 of
Appendix D of this Agreement, received for the grant of each sublicense in respect of the Licensed Patent Rights in the Territory. 
  

 APPENDIX E 
  

COMMERCIAL DEVELOPMENT PLAN 
  
 RESEARCH, DEVELOPMENT AND MARKETING PLAN 
 “Methods of Protecting Vasculature From Damage by Diphtheria Toxin and Pseudomonas 
 Toxin-based Immunotoxins During Therapy: Vascular Protection by Chloroquine During Brain 
 Tumor Therapy with Tf-CRM107/NC
66000” 
  
 May 28, 2002 
  
 DEVELOPMENT PLAN 
  
 CLINICAL REGULATORY 
  
 The above referenced technology will be used to reduce the neurotoxicity of the immunotoxin, Tf-CRM107 (also known as NC 66000). Animal Studies carried out by Dr. Richard
Youle (NIH) indicate that Chloroquine (an anti-malaria drug) increases the maximum tolerated dose of NC 66000 by 50%. 
  
 NC 66000 is a therapy that is currently directed at a specific niche; brain cancer patients. The clinical trials for Chloroquine/NC 66000 will also be directed to this
niche and will be conducted at a limited number of sites (approximately 10 to 15), to ensure that the neurosurgeons are well trained in the procedure and to ensure that safety issues can be evaluated and proper follow-up care is provided to
patients. These sites will most likely be the same sites where previous clinical trials for NC 66000 were conducted. Clinical Trials will begin with a single centre Phase I trial in the first half of 2003. These studies will establish the maximum
tolerated dose as well as Chloroquine’s safety profile when used in conjunction with NC 66000 therapy. Subject to regulatory and IRB approvals, a multicentre Phase 11 Clinical Trial is projected to begin the second half of 2004. A Phase III
Clinical Trial will follow beginning in the second half of 2006. It is expected that a BLA will be submitted during the second half of 2008. 
  
 MANUFACTURING 
  
 KS Avicenna, will be responsible for all activities associated with the manufacture of NC 66000 for the human clinical trials with Chloroquine. KS Avicenna will complete the final stages of manufacture of NC 66000 in
the second half of 2002 for use in the Phase I Chloroquine/NC 66000 Clinical Trial. 
  
 SALES PLAN 
  
 Once marketing approval is received for the use of
Chloroquine as an adjunct with NC 66000, the drug will be provided to hospitals that are familiar with the NC 66000 therapy. These will be hospitals where NC 66000 is currently in use. This ensures that procedures are followed and safety can be
evaluated. At peak penetration, it is expected that over 100 leading neuro-oncology centers and hospitals in the US will gain access to the NC 66000 technology. 
  

 Given the relatively small number of sites (when compared to other biopharmaceuticals), marketing efforts will be managed
by a direct sales force employed by KS Avicenna. In addition to the direct sales force, presentations at conferences, both academic/professional and industrial, such as the AANS (American Association of Neurological Surgeons) and publications in
academic and industrial journals including the internet will ensure that neurosurgeons and oncologists are aware of the Chloroquine/NC 66000 combination therapy and its benefits. 
  
 MARKET ANALYSIS 
  
 The clinical development of NC 66000 is focused on recurrent, inoperable, high grade glioma patients. The category of high-grade glioma (HGG) is defined to include
Glioblastoma Multiforme (GBM) and Anaplastic Astrocytoma (AA). According to estimates found in Future Oncology V3 (7/8), GBM and AA account for 41.8% and 5.9% of the total incidence of primary brain cancer, respectively. Patients with malignant
gliomas typically undergo surgery, radiation or chemotherapy in an attempt to prolong survival, but in almost all of them the gliomas will recur, which is also why this diagnosis is nearly uniformly fatal. Therefore, we assume that the incidence of
recurrent HGG is the same as the incidence of original HGG. To determine the number of inoperable tumors, we estimate that 65% of recurrent, high grade gliomas are inoperable. This estimate is based on discussions with neurosurgeons. 
  
 The incidences for high grade glioma (HGG) in the United States and Canada have been
extrapolated from 1997 estimates at an incidence of 20,000 using 1.17 % as the calculated annual increase in primary brain cancer incidence. (Future Oncology V3 (7/8), 1998). These calculations are used to obtain the total market size in patients
for this market segment. 
  
 The estimated projections for the market penetration
for immunotoxins and market share for the NC 66000 product are indicated in Table 2 below. NC 66000 sales will begin in 2005. As the first immunotoxin to market, NC 66000’s impressive efficacy will drive adoption to high levels. The penetration
rate for immunotoxins will increase to a peak penetration of 65% in 2010 to 2012 as physicians and clinical centres realize the benefits of this type of therapy. Market share projections assume that NC 66000 will be the first to the market and will
have two years of market exclusivity in years 2005 and 2006. Original estimates for market share projected that NC 66000 would maintain a leading market share until 2010 as first to the market for an unmet clinical need, would give NC 66000 a
significant advantage. 
  
 With the approval of the use of Chloroquine as an
adjunct to NC 66000 therapy by late 2008 or early 2009, NC 66000 will extend its position as a leader in the recurrent non-operable brain tumor market until 2014. The net effect of the use of Chloroquine will be to increase the number of patients
that could benefit from NC 66000 therapy thereby increasing NC 66000’s market share and net sales. Table 3 demonstrates the projected increase in market share and sales of NC 66000 that could occur with the use of Chloroquine. Use of
Chloroquine as an adjunct will increase the cumulative sales of NC-66000 by at least $58 million. 
  
 The improved safety profile of NC 66000 with Chloroquine will further expand the treatment population that may benefit from this novel therapy. Thus, in addition to non-operable recurrent HGG, the use of Chloroquine
may expand the use of NC 66000 to include operable tumors, 

  

 
lower grade gliomas and pediatric tumors. The increased sales projections in Table 3 are therefore very conservative and could be significantly higher.

  
 Sales projection estimates are calculated from assumptions about pricing over
the life of the product as well as the estimate that the average number of treatments per patient is 2. 
  

 TABLE 1 
 SCHEDULE
- CHLOROQUINE/ NC 66000 
  

																													
	 	  	2002

	  	2003

	  	2004

	  	2005

	  	2006

	  	2007

	  	2008

	 	  	H1

	  	H2

	  	H1

	  	H2

	  	H1

	  	H2

	  	H1

	  	H2

	  	H1

	  	H2

	  	H1

	  	H2

	  	H1

	  	H2

	 Regulatory
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 BLA Submission*
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 Clinical
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 Phase I Clinical Trials (Single Centre)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 Phase II Clinical Trials (Multi Centre)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 Phase III Clinical Trials (Multi Centre)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 CMC
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 Supply of Drug Substance (KS Avicenna)
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
															
	 *Approvals under the control of FDA
	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 

  

 TABLE 2 
 DISEASE
INCIDENCE AND SALES PROJECTIONS: 
  
 NC 66000 2002 to 2009

 NC 66000/Chloroquine 2009 to 2015 
  
 Market Segment: Non-operable HGG 
  
 o 
  

																																											
	 	  	2002

	 	 	2003

	 	 	2004

	 	 	2005

	 	 	2006

	 	 	2007

	 	 	2008

	 	 	2009

	 	 	2010

	 	 	2011

	 	 	2012

	 	 	2013

	 	 	2014

	 	 	2015

	 
	 o Incidence
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 U.S.A. Primary tumor +1.2% (note 1 & 2)
	  	18,649	 	 	18,867	 	 	19,080	 	 	19,309	 	 	19,534	 	 	19,761	 	 	19,992	 	 	20,224	 	 	20,460	 	 	20,698	 	 	20,940	 	 	21,183	 	 	21,430	 	 	21,680	 
	 Canada Primary tumor + 1.2% (note 1 & 2)
	  	2,299	 	 	2,326	 	 	2,353	 	 	2,381	 	 	2,408	 	 	2,436	 	 	2,465	 	 	2,494	 	 	2,523	 	 	2,552	 	 	2,582	 	 	2,612	 	 	2,642	 	 	2,673	 
	 HGG (%)
	  	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%	 	47.7	%
	 HGG patients
	  	9,993	 	 	10,109	 	 	10,227	 	 	10,346	 	 	10,466	 	 	10,588	 	 	10,712	 	 	10,836	 	 	10,963	 	 	11,090	 	 	11,220	 	 	11,350	 	 	11,483	 	 	11,616	 
	 HGG non-op, recurrent (%)
	  	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%	 	65	%
	 o
 HGG non-op, recurrent patients
	  	6,495	 	 	6,571	 	 	6,647	 	 	6,725	 	 	6,803	 	 	6,882	 	 	6,963	 	 	7,044	 	 	7,126	 	 	7,209	 	 	7,293	 	 	7,378	 	 	7,464	 	 	7,551	 
	 Penetration
 (Immunotoxins  % of patients)
	  	0	%	 	0	%	 	0	%	 	9	%	 	22	%	 	48	%	 	56	%	 	61	%	 	65	%	 	65	%	 	65	%	 	61	%	 	56	%	 	52	%
	 Treated patients
	  	 	 	 	 	 	 	 	 	 	605	 	 	1,497	 	 	3,303	 	 	3,899	 	 	4,297	 	 	4,632	 	 	4,686	 	 	4,740	 	 	4,500	 	 	4,180	 	 	3,927	 
	 Treatments patient
	  	 	 	 	 	 	 	 	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 	 	2	 
	 Total treatments
	  	 	 	 	 	 	 	 	 	 	1,210	 	 	2,994	 	 	6,606	 	 	7,798	 	 	8,594	 	 	9,264	 	 	9,371	 	 	9,480	 	 	9,000	 	 	8,360	 	 	7,854	 
	 o
 NC66000 Market Share
	  	 	 	 	 	 	 	 	 	 	100	%	 	100	%	 	85	%	 	70	%	 	70	%	 	70	%	 	70	%	 	65	%	 	60	%	 	50	%	 	47	%
	 	  	 	 	 	 	 	 	 	 	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

	 NC66000 Treatments
	  	 	 	 	 	 	 	 	 	 	1,210	 	 	2,994	 	 	5,615	 	 	5,459	 	 	6,016	 	 	6,485	 	 	6,560	 	 	6,162	 	 	5,400	 	 	4,180	 	 	3,691	 
	 Price per treatment
($ US) (note 5)
	  	 	 	 	 	 	 	 	 	 	7,500	 	 	7,203	 	 	7,059	 	 	6,918	 	 	6,644	 	 	6,511	 	 	6,381	 	 	6,253	 	 	6,128	 	 	6,005	 	 	5,885	 
	 	  	 	 	 	 	 	 	 	 	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

	 NC66000 Net Sales
($ US ‘000’s)
	  	 	 	 	 	 	 	 	 	 	9,075	 	 	21,566	 	 	39,636	 	 	37,765	 	 	39,970	 	 	42,224	 	 	41,859	 	 	38,531	 	 	33,091	 	 	25,101	 	 	21,722	 
	 	  	 	 	 	 	 	 	 	 	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

  

						
	 o
 Note 1: Number of cases per year per 1997 SEER Estimate per “CA a Cancer Journal” Prados, Berger &Wilson
	  	17,600	 	 	U.S.
	 	  	
	
	 	

	 o
	  	2,170	 	 	Canadian
	 	  	
	
	 	

	 Note 2: Annual Growth in Brain Tumors per 1997 SEER estimate
	  	1.17	%	 	 
	 o
 Note 3: HGG (%) is the incidence of Glioblastoma Multiforme and Anaplastic Astrocytoma, per 1997 SEER Estimate
	  	47.7	%	 	 
	 o
 Note 4: HGG non-op, recurrent (%) is the non-operable HGG of total HGG, as per Nycomed Amersham estimate
	  	65	%	 	 
	 o
 Note 5: Price per treatment begins at $US 7500 and declines each year after completion
	  	 	 	 	 

  

																																								
	 TABLE 3
 COMPARISON OF SALES
PROJECTIONS:
  
 NC 66000 Versus NC 66000/CHLOROQUINE
 Market Segment: Non-operable HGG
  
	 
	 	  	2002

	  	2003

	  	2004

	  	2005

	 	 	2006

	 	 	2007

	 	 	2008

	 	 	2009

	 	 	2010

	 	 	2011

	 	 	2012

	 	 	2013

	 	 	2014

	 	 	2015

	 
	 SALES ($ US 000’s)
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 NC 66000
	  	 	  	 	  	 	  	9,075	 	 	21,566	 	 	39,637	 	 	37,765	 	 	34,256	 	 	30,159	 	 	28,702	 	 	27,269	 	 	24,267	 	 	21,085	 	 	18,491	 
	 NC 66000/Chloroquine
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	39,970	 	 	42,224	 	 	41,859	 	 	38,531	 	 	33,091	 	 	25,101	 	 	21,722	 
	 Increase in Sales due to Chloroquine use
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	5,714	 	 	12,065	 	 	13,157	 	 	11,262	 	 	8,824	 	 	4,016	 	 	3,231	 
	 % Increase
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	16.7	%	 	40.0	%	 	45.8	%	 	41.3	%	 	36.4	%	 	19.0	%	 	17.5	%
	 MARKET SHARE: % of Immunotoxin Market
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 NC 66000
	  	 	  	 	  	 	  	100	%	 	100	%	 	85	%	 	70	%	 	60	%	 	50	%	 	48	%	 	46	%	 	44	%	 	42	%	 	40	%
	 	  	 	  	 	  	 	  	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

	 NC 66000/Chloroquine
	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	70	%	 	70	%	 	70	%	 	65	%	 	60	%	 	50	%	 	47	%
	 	  	 	  	 	  	 	  	 	 	 	 	 	 	 	 	 	 	 	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	
	 	
	

  

 APPENDIX F 
 BENCHMARKS 
  
 Licensee agrees to the
following Benchmarks for its performance under this Agreement and, within thirty (30) days of achieving a Benchmark, will notify PHS that the Benchmark has been achieved. 
  

			
		
	Begin Phase I Clinical Trials	  	1st Half, 2003
		
	Begin Phase II Clinical Trials	  	2nd Half, 2004
		
	Begin Phase III Clinical Trials	  	2nd Half, 2006
		
	BLA Submission	  	2nd Half, 2008
		
	Product Launch	  	Six months after receipt of the BLAAgreement between KS Biomedix Holdings PLC and Sosei CO, LTD

 Exhibit 4.23 
  

	*	CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.

  
 DATED November 1st, 2002

  
 KS BIOMEDIX HOLDINGS PLC 
  
 -and- 
  
 SOSEI CO., LTD. 
  
 LICENCE AGREEMENT 
  

 THIS AGREEMENT is made the 1st day of November, 2002 
  
 BETWEEN: 
  

	1.	KS BIOMEDIX HOLDINGS PLC a company incorporated in England (Registration Number 3006674) whose registered office is at 42-46 High Street, Esher, Surrey, KT10 9QY, England
(“KSB”); and 

  

	2.	SOSEI CO, LTD., a company incorporated in Japan whose registered office is at 4F Kojimachi NK Bldg., 2-14-2 Kojimachi, Chiyoda-ku, Tokyo, Japan (“SOSEI”);

  
 WHEREAS 
  

	A.	KSB has a certain pharmaceutical product under development for use in the therapy and prophylaxis of brain cancers. 

  

	B.	KSB wishes to grant to SOSEI, and SOSEI wishes to accept, the exclusive rights and licenses to market, distribute, sell and/or sub-license such a product in Japan upon the terms
contained in this Agreement. 

  

	C.	KSB and SOSEI have agreed to collaborate in such further development of said product as may be required to obtain marketing authorisations for said product in Japan.

  
 NOW IT IS HEREBY AGREED as follows: 
  

	1.	DEFINITIONS 

  

	1.1	In this Agreement, unless the context otherwise requires: 

  

	 	1.1.1 	“Active Ingredient” shall mean CRM107 conjugated to human transferrin; 

  

	 	1.1.2 	“Affiliate” means in relation to either party any person who directly or indirectly controls, is controlled by or is under common control with that party. A person
shall be regarded as in control of another person if it owns directly or indirectly more than 40% (forty per cent) of the voting stock or other ownership or income interest of another person or if it directly or indirectly possesses the power to
direct or cause the direction of the management and policies of another person by any means whatsoever; 

  

	 	1.1.3 	“Business Day” means -a day other than a Saturday, Sunday, Bank Holiday or other public or national holiday in England or the Territory; 

 

	 	1.1.4 	 “Clinical Data” means the data from any Clinical Trials and any other test data related thereto and any other documentation or correspondence
relating to 

  

	 	 
any Clinical Trials of the Product conducted by or on behalf of either party hereto and all Know-how in respect of the same; 

  

	 	1.1.5 	“Clinical Development Plan” means the clinical development plan for the Product for carrying out the Clinical Trials which are necessary or desirable to obtain
Marketing Authorisation of the Product in the Territory; 

  

	 	1.1.6 	“Clinical Trials” means such clinical testing (including toxicological, stability, pharmacological and clinical studies in human beings) as may be required to be
carried out and/or produced by or on behalf of either party hereto in connection with obtaining the Marketing Authorisation for the Product either inside or outside of the Territory; 

  

	 	1.1.7 	“CMC Data” means those data required by Part 2 of the Annex to Directive 2001/83/EC including the qualitative and quantitative particulars of the constituents, the
description of the manufacturing method and the controls and tests carried out at all relevant stages of the manufacturing process of the Active Ingredient and/or the Product; 

  

	 	1.1.8 	“Commercial Launch” shall mean the first shipping by SOSEI, its Affiliate or Sub-Licensee of the Product to its wholesalers in the Territory in such commercial
quantities of the Product as may reasonably be appropriate to establish the Product throughout the Territory; 

  

	 	1.1.9 	“Controlled” means, with respect to a particular item, material or intellectual property right, that a party or an Affiliate of such party owns or has a license
under such item, material or intellectual property right and where licensed, has the ability to grant to the other party access to material or Intellectual Property right without violating the terms of such license and “Control”
shall be construed accordingly; 

  

	 	1.1.10 	“CRM 107” means single point mutated diptheria toxin; 

  

	 	1.1.11 	“Dossier” means the master regulatory dossier relating to the Product prepared by or on behalf of either party hereto in connection with obtaining the Marketing
Authorisations for the Product in and outside of the Territory, including relevant Clinical Data and CMC Data; 

  

	 	1.1.12 	“Effective Date” means the execution date of this Agreement parties hereto; 

  

	 	1.1.13 	“EU” means the European Union and each of the member states from time to time of the European Union; 

  

	 	1.1.14 	“Filing Date” means the date upon which a Dossier for the Product was submitted by or on behalf of SOSEI in support of an application for the Marketing
Authorisation of the Product in the Territory; 

  

 3 

	 	1.1.15 	“Force Majeure” means in relation to either party any circumstances beyond the reasonable control of that party including without limitation any strike, lock-out or
other form of industrial action, act of God, war, riot, accident, fire, flood, explosion or government action 

  

	 	1.1.16 	“Indications” means progressive or recurrent glioblastoma multiforme, newly diagnosed malignant glioma, metastatic brain tumours and any other indications that the
parties agree from time to time in writing. ; 

  

	 	1.1.17 	“Intellectual Property” means all patents, claims in patents, trademarks and trade names, service marks, registered designs, applications for any of the foregoing
and the right to apply for any of the foregoing in any part of the world, copyright, design right, inventions, confidential information (including Know how) and any other similar right situated in any country of the world. 

 

	 	1.1.18 	“Know-how” means all information relating to CRM107, the Active Ingredient and/or the Product not in the public domain of whatsoever nature, including ideas,
discoveries, inventions, data, formulae, techniques, procedures for experiments and tests, designs, sketches, records, biological materials and confidential analyses and interpretations of information which is in the public domain;

  

	 	1.1.19 	“KSB Patents” means patent(s) and patent application(s) to be filed by KSB in the Territory during the term of this Agreement with respect to the Active Ingredient
and/or the Product, including all extensions, additions and divisions thereof. 

  

	 	1.1.20 	“Launch Date” means the date of Commercial Launch by SOSEI of the Product in the Territory after all necessary Marketing Authorisations have been obtained by SOSEI
in the Territory; 

  

	 	1.1.21 	“LIBOR” means the rate per annum (rounded upwards if necessary to the next higher 1/100th of 1%) which is the average of the inter bank offered rates for US Dollar
deposits in the London inter bank Euro Dollar Market for a period of five consecutive Business Days as reported in the Financial Times newspaper in its “Money Rates” column on the relevant date or if the Financial Times does not publish
such rate for any reason, such rate as is quoted by Reuters at 10.00 am (London time) on such date or (if the relevant date is not a Business Day) on the first Business Day following the relevant date; 

  

	 	1.1.22 	“Marketing Authorisation” means all approvals (including price and reimbursement approvals, if applicable), licenses, registrations or authorisations of any
federal, national, state, provincial or local regulatory agency, department, bureau or other government entity necessary for the commercial marketing, sale and use of the product in the Territory; 

  

 4 

	 	1.1.23 	“Medical Affairs Liaison” means persons appointed by KSB and SOSEI to communicate with each other with regard to information to be exchanged pursuant to Clause 7.

  

	 	1.1.24 	“Net Sales” means all monies invoiced by SOSEI or its Affiliates or any Sub-Licensees in respect of the sale by SOSEI, its Affiliates or any Sub-Licensees of the
Product to an independent third party less the following items to the extent that they are actually paid or allowed and specified on any documents related to such sale: 

  

	 	(i)	normal discounts actually granted (including for the avoidance of doubt reimbursement to a customer of promotional costs); 

  

	 	(ii)	credit actually allowed for any Product returned or not accepted by customers; 

  

	 	(iii)	packaging, transportation and prepaid insurance charges on shipments or deliveries to customers; and 

  

	 	(iv)	sales or value added taxes actually incurred and paid by SOSEI, its Affiliates or any Sub-licensees in connection with the sale or delivery of the Products to customers;

  
 Provided That: the Product reasonably supplied
as samples shall not be treated as being disposed of on a commercial basis and shall be ignored for the purpose of calculating the Net Sales; 
  

	 	1.1.25 	“Orphan Medicine Status” means the designation by the Regulatory Authority in the Territory as an orphan drug after filing an application for obtaining such status
of the Product with the Regulatory Authorities in the Territory; 

  

	 	1.1.26 	“Product” means any pharmaceutical product in finished dosage or in finished dosage package form ready for sale to third parties which consists of or contains the
Active Ingredient for human use; 

  

	 	1.1.27 	“Quarter” means each three calendar-month period in any year during the term of this Agreement ending on 31st March, 30th June, 30th September and 31st December in
each year and “Quarterly” has a corresponding meaning; 

  

	 	1.1.28 	“Regulatory Authority” means the body with responsibility for granting the Marketing Authorisations of the Product; 

  

	 	1.1.29 	“Royalties” means the royalties payable to KSB in accordance with Clause 11; 

  

 5 

	 	1.1.30 	“SOSEI Trademark” means any trademark or name or logo proprietary to SOSEI used on products marketed by SOSEI (in addition to any mark, logo or name identifying the
product) to identify SOSEI as the holder of a Marketing Authorisation for such product; 

  

	 	1.1.31 	“Sub-licence” means any sublicense agreement entered into by SOSEI (or any Affiliate of SOSEI) and a Sub-Licensee, pursuant to which SOSEI (or such SOSEI Affiliate)
grants such Sub-Licensee rights to market, distribute and sell the Product in the Territory, or any part thereof, 

  

	 	1.1.32 	“Sub-Licensee” means any person (including distributors but excluding for the avoidance of doubt any SOSEI Affiliates) to whom SOSEI has directly or indirectly,
granted rights to market, distribute or sell the Product in any part of the Territory; 

  

	 	1.1.33 	“Supply Agreement” means the supply agreement between the parties to be entered into in accordance with Clause 8; 

  

	 	1.1.34 	“Territory” means Japan; 

  

	 	1.1.35 	“Trademarks” means the trade names and marks (both registered and unregistered) selected by SOSEI in respect of the Product in the Territory and notified to KSB
under the terms of Clause 9.1; 

  

	 	1.1.36 	“Year” means a calendar year commencing from 1st January. 

  

	1.2	In this Agreement unless the context otherwise requires: 

  

	 	1.2.1 	references to “this Agreement” shall mean this Agreement and any and all Schedules to it as may be varied from time to time in accordance with its provisions;

  

	 	1.2.2 	all references to a particular Clause, Schedule or paragraph shall be a reference to that Clause, Schedule or paragraph in the Agreement; 

  

	 	1.2.3 	words importing the singular shall include the plural and vice versa and words importing the masculine gender shall include the feminine gender and vice versa;

  

	 	1.2.4 	headings are for convenience only and shall be ignored in interpreting this Agreement; 

  

	 	1.2.5 	unless the contrary intention appears words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust, association, organisation or
other entity, in each case whether or not having separate legal personality; 

  

 6 

	 	1.2.6 	the words “include” or “including” are to be construed without limitation to the generality of the preceding words; 

  

	 	1.2.7 	references to a statute include any statutory modification, extension or re-enactment of that statute; and 

  

	 	1.2.8 	any reference to “writing” or any cognate expression includes a reference to any communication effected by facsimile transmission, electronic mail or similar means.

  

	2.	GRANT OF LICENSE 

  

	2.1	KSB hereby grants to SOSEI and its Affiliate an irrevocable and exclusive licence to market, promote, distribute, sell and/or Sub-license the Product in the Territory during the
term of this Agreement. 

  

	3.	DISCLOSURE OF TECHNICAL INFORMATION AND OTHER KNOW-HOW 

  

	3.1	Promptly after execution but within 45 (forty-five) days at the latest following the Effective Date, KSB shall disclose SOSEI any and all technical information in its possession
relating to CRM 107, the Active Ingredient and/or the Product, which have not yet been disclosed to SOSEI, including but not limited to preclinical data, Clinical Data, clinical development plan, CMC Data, Know-how and Dossier, if any, for CRM 107,
the Active Ingredient and/or the Product. KSB shall also disclose to SOSEI within 90 (ninety) days all of such technical information which KSB may develop or acquire during the term of this Agreement, including all of such technical information that
KSB will obtain from its sub-licensee(s), if any, outside of the Territory. It is, however, agreed and understood that KSB is required to disclose SOSEI any such technical information relating to the manufacture of CRM 107, the Active Ingredient and
the Product only to the extent that SOSEI is required to incorporate in its documents to be submitted to the Regulatory Authority in the Territory for commencing the Clinical Trials of the Product or in the Dossier to be filed with the Regulatory
Authority in the Territory 

  

	3.2	SOSEI shall have the right to use such technical information disclosed to it pursuant to Clause 3.1 for the purpose of this Agreement and to disclose it to its Affiliates and
Sub-Licensees for their use for the purpose of this Agreement, subject to Clause 13. 

  

	4.	CLINICAL DEVELOPMENT: INITIAL INDICATION PRODUCT 

  

	4.1	SOSEI shall use all reasonable endeavours at its sole expense to pursue Clinical Trials and to develop and create the Dossier for the Product in the Territory.

  

	4.2	SOSEI shall within 90 (ninety) days following the Effective Date, discuss with KSB and determine a Clinical Development Plan in the Territory together with a timetable for all
required actions and the anticipated Filing Date for the Product in the Territory 

  

 7 

	4.3	SOSEI shall use its reasonable efforts to implement the Clinical Development Plan in accordance with a timetable agreed in the Clinical Development Plan and also in accordance with
the terms of this Agreement. 

  

	4.4	All Clinical Data generated by SOSEI hereunder shall solely belong to SOSEI 

  

	4.5	SOSEI shall submit to KSB the estimated quantities of the Product necessary for carrying out the Clinical Trials and any other tests and studies of the Product in the Territory
which SOSEI, its Affiliates and Sub-Licensees require for the preparation of the Dossier to be filed with the Regulatory Authorities for obtaining the Marketing Approval of the Product in the Territory, together with timing of delivery of such
quantities of the Product. KSB shall supply SOSEI with all of such quantities of the Product in such form as shall be then agreed upon between the parties in writing at the cost price to KSB of such Product. 

  

	5.	MARKETING AUTHORISATIONS 

  

	5.1	SOSEI shall, subject to the provision by KSB to SOSEI of all relevant and necessary technical information promptly after the Effective Date, complete within 60 (sixty) days
following the Effective Date preparation of all necessary documentations for submitting to the Regulatory Authority in the Territory an application for obtaining the Orphan Medicine Status of the Product and start promptly thereafter negotiations
with the Regulatory Authority in the Territory for obtaining the Orphan Medicine Status of the Product. SOSEI shall as soon as reasonably practicable file the Dossier in respect of the Product with the Regulatory Authority in the Territory and shall
use all best endeavours to obtain a Marketing Authorisation of the Product in the Territory 

  

	5.2	SOSEI shall be solely responsible for effecting (at its sole cost and expense) such amendments to the Dossiers as may be required after filing with the appropriate Regulatory
Authority in the Territory to procure that the Dossier complies with and satisfies the requirements of the Regulatory Authority in connection with obtaining the Marketing Authorisation of the Product in the Territory. 

  

	5.3	SOSEI shall promptly furnish to KSB and in any event on KSB’s written request, a copy of each Dossier as submitted to the Regulatory Authority in the Territory, including a
copy of any supplemental documents submitted to the Regulatory Authority in the Territory in respect of such Dossier. 

  

	5.4	SOSEI shall use all reasonable endeavours to procure and maintain the maximum period of data exclusivity in the Territory in respect of the Dossiers filed by SOSEI in connection
with any application for or the maintenance of any Marketing Authorisation of the Product in the Territory. 

  

	5.5	 In the event that the filing of an application for obtaining the Marketing Authorisation of the Product by KSB for any Indications other than progressive or
recurrent glioblastoma multiforme in any major country consisting of USA and member countries of the EU is rejected or significantly delayed, the parties will jointly review and agree the commercial 

  

 8 

	 	 
viability of pursuing clinical development and regulatory submission for such other Indications of the Product in the Territory.

  

	6.	MARKETING 

  

	6.1	Not less than 60 (sixty) days prior to the anticipated first Launch Date of the Product and thereafter not less than 60 (sixty) days prior to commencement of each Year following
said Launch Date, SOSEI shall provide to KSB an annual marketing plan (in case of the first plan, for the remaining period of the Year to which said first Launch Date belongs) outlining the positioning of the Product, sales materials, trade show
support and educational campaigns for the Product in the Territory and a sales forecast for the Year covered by such annual marketing plan. 

  

	6.2	SOSEI shall during the term of this Agreement at its own cost, use all commercially reasonable efforts to: 

  

	 	6.2.1 	effect Commercial Launch of the Product in the Territory as soon as reasonably possible after obtaining Marketing Authorization of the Product; 

  

	 	6.2.2 	initiate, extend, develop, promote and maximise sales of the Product in the Territory and not to do anything which may hinder or interfere with such sales; 

 

	 	6.2.3 	achieve the sales forecasts contained in the relevant annual marketing plan; 

  

	 	6.2.4 	allocate such promotional and sales resources and such technical support for the promotion, marketing and sales of the Product as may reasonably be required to maximise sales of the
Product in the Territory. 

  

	6.3	SOSEI agrees and undertakes to market, sell and distribute the Product in the Territory entirely in accordance with the Marketing Authorization of the Product and any other
applicable laws, restrictions and regulations. 

  

	6.4	KSB shall have the right at its own expense to undertake or send one or more representatives to any exhibition, scientific symposia and conference related to the Product in the
Territory in collaboration with SOSEI. 

  

	7.	PRODUCT SAFETY AND LIABILITY 

  

	7.1	Within 60 (sixty) days of the Effective Date, each party shall appoint a primary liaison person (“Medical Affairs Liaison”) to communicate with each other with regard to
information to be exchanged pursuant to this Clause 7. 

  

	7.2	 SOSEI shall be responsible for the maintenance of the central database for the Territory regarding all adverse drug reactions, suspected adverse drug reactions and
other medical and technical information relevant to the safety of the Product and shall make the central 

  

 9 

	 	 
database available to the KSB Medical Affairs Liaison or such other KSB representatives as agreed upon from time to time in writing between the parties.

  

	7.3	During the term of this Agreement, KSB shall inform SOSEI of any adverse drug reaction or suspected adverse drug reaction affiliated with the Product anywhere in the world outside
of the Territory about which KSB obtains information in accordance with the following: 

  

	 	7.3.1 	any serious adverse drug reaction information obtained by KSB shall be reported to SOSEI’s Medical Affairs Liaison by telephone or in writing within 5 (five) Business Days
after initial determination by KSB that the adverse drug reaction is serious and any non serious adverse drug reaction information within 90 (ninety) days after the initial receipt by KSB of the information; 

  

	 	7.3.2 	KSB’s reports shall contain any relevant information reasonably required by SOSEI and shall also be sufficient in content to meet the requirements of the Regulatory Authority
in the Territory with respect to the adverse drug reaction reports and ICH periodic drug safety updates. 

  

	7.4	During the term of this Agreement, SOSEI shall inform KSB of any adverse drug reaction of suspected adverse drug reaction affiliated with the Product in the Territory about which
SOSEI obtains information in accordance with the following: 

  

	 	7.4.1 	any serious adverse drug reaction information obtained by SOSEI shall be reported to KSB’s Medical Affairs Liaison by telephone or in writing in English within 5 (five)
Business Days after initial determination by SOSEI that the adverse drug reaction is serious and any non serious adverse drug reaction information within 90 (ninety) days after the initial receipt by SOSEI of the information;

  

	 	7.4.2 	SOSEI’s reports shall contain any relevant information reasonably required by KSB and shall also be sufficient in content to meet the requirements of CIOMS I expedited adverse
drug reaction reports and ICH periodic drug safety updates. 

  

	7.5	SOSEI shall have responsibility for investigating adverse drug reactions affiliated with the Product and for reporting them to the Regulatory Authorities in the Territory, where
appropriate, in accordance with the laws and regulations of the Territory and for effecting any required safety updates of the Product in the Territory. Each Party shall promptly deliver to the other all correspondence that it receives from any
Regulatory Authorities relating to the safety of the Product except for procedural, non-substantive communications. 

  

	7.6	 SOSEI may at its discretion and will if requested to do so by KSB, recall any Product in the Territory. The costs and expenses incurred by SOSEI, its Affiliates
and/or Sub-Licensees in connection with such recall shall be borne by SOSEI, unless such recall is 

  

 10 

	 	 
the request of KSB in which case KSB shall reimburse to SOSEI all of such costs and expenses. 

  

	7.7	SOSEI shall insure the Product against all product liability claims arising in respect of the Product supplied by SOSEI in the Territory, regardless of whether or not arising as a
result of the negligence or breach of this Agreement by SOSEI. 

  

	8.	MANUFACTURING AND SUPPLY 

  

	8.1	The parties will enter into the Supply Agreement, to be negotiated in good faith and entered into by the parties within 90 (ninety) days of the Effective Date substantially upon the
terms of the Schedule I attached hereto. 

  

	9.	TRADEMARKS AND PACKAGING 

  

	9.1	SOSEI may in its sole discretion (subject always to the terms of this Clause 9) select the Trademark for use on the Product in the Territory. SOSEI shall notify KSB of its choice of
the Trademark on effecting first filing for the Marketing Authorisation of the Product and shall notify KSB in the event that it is required by any Regulatory Authority to amend or change such Trademark. 

  

	9.2	SOSEI shall not use any trademark or name on or in connection with the Product other than the Trademark without the prior approval of KSB, such approval not to be unreasonably
withheld or delayed and shall warrant that the Trademark will not infringe any third party’s rights and indemnify KSB if it suffers liability due to a breach of this warrant the Trademark shall not be the one confusingly similar to, or
identical to any existing KSB proprietary mark or logo. 

  

	9.3	Apart from the Trademark and any SOSEI Trademark or logo, no other trademark or logo may be affixed to the Product in any form whatsoever. SOSEI shall not use in its business any
other trademark confusingly similar to the Trademark and shall not use the Trademark as or as part of any corporate or trading name of SOSEI or any SOSEI Affiliate. 

  

	9.4	SOSEI undertakes: 

  

	 	9.4.1 	to develop and design labelling and packaging for the Product in the Territory at its sole cost and expense provided always that the general quality, design and content of such
labelling, packaging and any information supplied with the Product by SOSEI shall be submitted to KSB for its reference and information. SOSEI acknowledges that SOSEI shall be solely responsible for the labelling and packaging of the Product and
compliance with its obligations under this Clause 9; and 

  

	 	9.4.2 	 not to use any misleading statements or misrepresentations on the Product packaging or use any defective packaging materials and to comply in all respects with all
local regulations and laws and the Marketing Authorisations 

  

 11 

	 	 
of the Product in connection with the Product labelling, packaging and the information provided thereon; and 

  

	 	9.4.3	not to use any packaging which may adversely affect the Product in any way whatsoever, including the Product’s approved shelf-life. 

  

	10.	REPRESENTATIONS BY AND AUTHORITY OF SOSEI 

  

	10.1	SOSEI undertakes: 

  

	 	10.1.1 	not to represent itself to any third party as the legal agent of KSB in any manner and clearly to indicate in all correspondence and dealings relating directly or indirectly to the
sale or other disposition of the Product under this Agreement that it is acting as principal; and 

  

	 	10.1.2 	not to bind or purport to bind or indicate any authority to bind KSB (or otherwise any KSB Affiliate) to any contract whatsoever, unless otherwise agreed upon between the parties;
and 

  

	 	10.1.3 	Not to use the corporate name or logo of KSB (or otherwise the corporate name of any KSB Affiliate) in any manner whatsoever; and 

  

	 	10.1.4 	not to incur any liability on behalf of KSB or in any way pledge or purport to pledge KSB’s credit or accept any order or make any contract binding upon KSB or give or make or
purport to give or make any promises representations warranties or guarantees with reference to the Product on behalf of KSB except such as are expressly authorised by KSB in writing. 

  

	10.2	SOSEI hereby confirms that nothing contained in this Agreement shall give or be deemed to give it any authority to negotiate the sale or purchase of the Product on behalf of KSB or
to negotiate and conclude such transactions on behalf of KSB. 

  

	10.3	SOSEI shall be solely responsible for the acts and omissions of its employees and representatives in connection with the performance of its rights and obligations under this
Agreement. 

  

	11.	PAYMENTS 

  

	11.1	In consideration of the rights and licenses granted hereunder to SOSEI in respect of the Product SOSEI shall pay to KSB: 

  

	 	11.1.1 	the sum of US $* United States Dollars) within 30 (thirty) Business Days following the Effective Date. 

  

	 	11.1.2 	the sum of US $* United States Dollars) following the receipt of Orphan Drug Status in the Territory ; 

  

 12 

	 	11.1.3 	the sum of US $* United States Dollars) following a regulatory submission to initiate the first pivotal studies of the Product in patients with newly diagnosed glioma in either of
USA or EU; 

  

	 	11.1.4 	the sum of US $* United States Dollars) following the first filing of an application for obtaining the Marketing Authorization of the Product in the Territory;

  

	 	11.1.5 	the sum of US $* United States Dollars) following the Launch Date for the first Indication of the Product (i.e. treatment of refractory high-grade glioma in adults) in the
Territory; 

  

	 	11.1.6 	the sum of $* United States Dollars) following the filing of an application for obtaining the Marketing Authorization for the second Indication of the Product (i.e. treatment of
newly diagnosed glioma) in the Territory; 

  

	 	11.1.7 	the sum of US $* United States Dollars) following the Launch Date for the second Indication of the Product in the Territory; 

  

	 	11.1.8 	the sum of US $* United States Dollars) following the filing of an application for obtaining the Marketing Authorization for the third Indication of the Product (i.e. treatment of
metastatic brain cancer) in the Territory; 

  

	 	11.1.9 	the sum of US $* United States Dollars) following the Launch Date for the third Indication of the Product in the Territory; 

  

	 	11.1.10 	the sum of US $* United States Dollars) one time payment within 90 (ninety) days of the end of the first Year in which an annual Net Sales of the Product equals or exceeds at the
first time US $* United States Dollars) in the Territory; 

  

	 	11.1.11 	the sum of US $* United States Dollars) one time payment within 90 (ninety) days of the end of the first Year in which an annual Net Sales of the Product equals or exceeds at the
first time US $* United States Dollars) in the Territory; 

  

	 	11.1.12 	the sum of US $* United States Dollars) one time payment within 90 (ninety) days of the end of the first Year in which an annual Net Sales of the Product equals to or exceeds at the
first time $* United States Dollars) in the Territory; 

  

	 	11.1.13 	the sum of US $* United States Dollars) one time payment within 90 (ninety) days of the end of the first Year in which an annual Net Sales of the Product equals or exceed at the
first time US $* United States Dollars) in the Territory; 

  

	 	11.1.14 	 the sum of US $* United States Dollars) one time payment within 90 (ninety) days of the end of the first Year in which aggregate Net Sales equal or exceed 

  

 13 

	 	 
US $* in the Territory, this milestone payment to be forgone if neither treatment of newly-diagnosed glioma nor metastatic brain cancers is approved in the
Territory; 

  

	 	11.1.15 	the Royalty equal to * of the Net Sales in the Territory, provided, however, that in the event that all of the Patents in the Territory do not mature into letters patent or expire
before termination of this Agreement and as a consequence, a competing product incorporating the Active Ingredient is marketed in the Territory for the treatment of brain cancers, the rate of the Royalty shall be reduced to * of the Net Sales during
the remaining term of this Agreement. 

  

	11.2	SOSEI shall notify KSB promptly of any determination, filing or approval that would trigger a payment by SOSEI to KSB under Clauses 11.1.1 through 11.1.9 and the amount of the
payment required. KSB shall, after. such notification, invoice SOSEI for such amount and SOSEI shall pay such amount to KSB within 30 (thirty) Business Days of receipt of such invoice. Payments under Clauses 11.1.10 through 11.1.14 shall be due
within 30 (thirty) Business Days following the submission of the statement by SOSEI to KSB under Clause 12.1 for the last Quarter of the Year in which the relevant annual Net Sales shall be achieved and shall be paid in accordance with Clause 12.

  

	12.	PAYMENT: GENERAL 

  

	12.1	SOSEI shall following the first Launch Date prepare a statement in respect of each Quarter which shall show for the Quarter in question the aggregate Net Sales. Such statement shall
be submitted to KSB within 60 (sixty) days of the end of the Quarter to which it relates together with remittance for the Royalties in respect of such Quarter. 

  

	12.2	SOSEI shall during the term of this Agreement following the first Launch Date keep true and accurate records of all Net Sales and books of account containing all the data necessary
for the calculation of the Royalties and other payments due under this Agreement. Such records and books of account shall, on reasonable prior written notice having been given by KSB, be open during normal working hours on any Business Day for
inspection by a public accounting firm of KSB’s own selection, except one to which SOSEI or its Affiliate or Sub-licensee may have reasonable objection, not more often than once each Year, for not more than 3 (three) previous Years. KSB may
exercise such right until the end of 1 (one) year after termination or expiration of this Agreement. The cost of such inspection shall be borne by KSB and, if such inspection reveals an underpayment of the Royalties, SOSEI shall pay such
underpayment Promptly upon receipt of an invoice in respect of the same, together with interest in accordance with Clause 12.3. Said public accounting firm shall treat confidential, and shall not disclose to KSB, any information other than
information which shall be given to KSB pursuant to any provision of this Agreement. 

  

	12.3	 Without prejudice to KSB’s rights of termination under Clause 16 of this Agreement, if any Royalty or milestone payment under Clause 11.1 or any part thereof
is overdue SOSEI shall pay interest thereon at an annual rate (but with interest accruing on a daily 

  

 14 

	 	 
basis) at 3 % (three percent) above LIBOR, such interest to run from the date upon which payment of such sum became due until payment thereof in full
together with such interest by SOSEI (whether before or after any judgement). 

  

	12.4	All sums due to KSB under this Agreement: 

  

	 	12.4.1 	are, unless otherwise expressly stated, exclusive of any Value Added Tax or equivalent sales tax which shall be payable (if applicable) on submission by KSB of valid Value Added Tax
invoices in respect thereof; and 

  

	 	12.4.2 	shall be paid in full without deduction of withholding taxes, charges and other duties except insofar as KSB shall be capable of obtaining a full credit therefor. The parties agree
to co-operate in all respects necessary to take advantage of such double taxation agreements as may be available. 

  

	12.5	All Royalties or other sums payable under this Agreement shall be paid in United States Dollars (“US$”). Where any Royalties or other sums falling due in any period
covered by the written statements referred to in Clause 12.1 are calculated in a currency other than US$, they shall be converted into US$ by reference to: 

  

	 	12.5.1 	the exchange rate applying when the monies are actually converted into US$ if this occurs during the period covered by the written statement referred to in Clause 12.1; or

  

	 	12.5.2 	in the event the monies are not actually converted into US$, the exchange rate of Barclays Bank plc ruling in London on the last day of the Quarter covered by the written statement
referred to in Clause 12.1. 

  

	13.	CONFIDENTIALITY 

  

	13.1	SOSEI undertakes that in relation to all confidential information which has been disclosed to SOSEI pursuant to any provision of this Agreement or which it may generate during the
term of this Agreement (such confidential information to include all information relating to CRM107, the Active Ingredient and/or the Products and to include all Clinical Data and CMC Data and the Dossier) (collectively “Confidential
Information”), it will keep the same secret and confidential, will use the same only to the extent as may reasonably be required in connection with the performance of its obligations under this Agreement and will not at any time for any reason
whatsoever disclose or permit the same to be disclosed to any third party (save as provided in Clause 13.4 below). 

  

	13.2	 KSB undertakes that in relation to all Confidential Information which has been disclosed to KSB pursuant to any provision of this Agreement, it will keep the same
secret and confidential, will use the same only to extent as may reasonably be required in connection with securing the Marketing Authorization of any products which contains or consists of the Active Ingredient in any countries outside of the
Territory and will not at 

  

 15 

	 	 
any time for any reason whatsoever disclose or permit the same to be disclosed to any third party (save as provided in Clause 13.4 below)

  

	13.3	The obligations of confidentiality contained in this Clause 13 shall not extend to any part of the Confidential Information which the recipient of such Confidential Information can
show by documentary evidence 

  

	 	13.3.1 	is prior to the date upon which it was received from the other party or becomes (otherwise than by reason of any default by such recipient) freely available to the general public:
or 

  

	 	13.3.2 	was legally in the possession or control of such recipient prior to the date upon which it was received from the other party, free of any obligation of confidentiality; or

  

	 	13.3.3 	came into its possession or control legally from a third party free of any obligation of confidentiality and otherwise than by reason of any breach of any obligation of
confidentiality by such third party subsequent to the date of this Agreement. 

  

	13.4	In the event that either party is required at any time whilst it shall retain any Confidential Information received from the other party under this Agreement by any relevant law or
regulation to disclose all or any part of such Confidential Information: 

  

	 	13.4.1 	it shall forthwith notify the other party of such part of the Confidential Information as may be required to be disclosed by law, the extent to which such disclosure is required and
the circumstances in which such disclosure is required or effected pursuant to any applicable law; and 

  

	 	13.4.2 	it shall keep the other party informed of the extent and nature of such disclosure; and 

  

	 	13.4.3 	it shall ensure that any party to whom all or any part of the Confidential Information is disclosed by reason of any disclosure required by law is made fully aware of the
confidentiality obligations attaching to the Confidential Information and shall (insofar as is possible) procure an equivalent obligation of confidentiality from any such party. 

  

	13.5	Notwithstanding the provisions of this Clause 13, either party shall be entitled to disclose Confidential Information received from the other party hereunder to its Affiliates and
Sub-Licensees and their agents, representatives, employees consultants, actual and potential investors (collectively “Third Party Recipients”) to the extent necessary to facilitate the performance of its obligations hereunder and as may be
required to exercise the rights granted to it hereunder. Provided that any such disclosure is limited only to what is necessary to effect the same and it shall procure that any Third Party Recipient shall be bound by obligations of confidentiality
substantially similar to the provisions of this Clause 13. 

  

 16 

	13.6	The parties undertake to continue to comply with the provisions of the Confidentiality Agreement dated April 11, 2001. Provided that in the event of any ambiguity or discrepancy
between this Agreement and the Confidentiality Agreement the terms of this Agreement shall prevail. 

  

	13.7	Subject to the provisions of Clause 13.8 neither party shall issue any press release or communication to be published by or in the media in any manner concerning the subject matter
of this Agreement without the prior written consent of the other party (such consent not to be unreasonably withheld or delayed). 

  

	13.8	If any announcements concerning the transaction contemplated by this Agreement or any ancillary matter is required by a party by law or any securities exchange or regulatory or
governmental body to which either party is subject or otherwise reasonably required to be made by any party in connection with information supplied to its shareholders from time to time, the announcement shall only be made after consultation with
and the prior agreement of the other party as to the terms and timetable for publication of any announcement (such consultation or prior agreement to be sought within a reasonable timescale and not to be unreasonably withheld or delayed by the other
party). 

  

	13.9	The obligations of both parties under this Clause 13 shall remain in force during the term of this Agreement and continue thereafter for a period of 5 (five) years.

  

	14.	Product Liability 

  

	14.1	KSB shall indemnify and hold SOSEI, its Affiliates and Sub-Licensees and their employees, agents, directors, officers and consultants harmless from any liability for costs and
damages in respect of claims made against it for death or personal injury which has resulted from the use of the Product purchased from KSB and which is attributable to the nature and properties of the Product, except to the extent that such death
or personal injury has resulted from any negligent act or default or omission of SOSEI, its Affiliates or Sub-Licensee or their respective employees, agents, directors, officers or consultants whether in the labelling, packaging, sales, or promotion
of the Product, subject to the following or where the any Product defect was reasonably discoverable upon inspection by SOSEI: 

  

	 	14.1.1 	SOSEI shall comply with all terms of this Agreement relating to the Product, 

  

	 	14.1.2 	SOSEI shall observe all reasonable instructions given by KSB in respect of the Product, including instructions as to warning to be given with respect to potential and actual adverse
effects of the Product and instructions to cease the sale of the Product because of such potential or actual adverse effects, 

  

	 	14.1.3 	SOSEI shall immediately advise KSB in writing of any previously unknown adverse reactions of which it may become aware and which may possibly be attributable to the Product, whether
or not SOSEI considers such reaction to have been caused by the Product, 

  

 17 

	 	14.1.4 	SOSEI shall immediately advise KSB of, and permit KSB to have full control of, any legal proceedings brought by any third party and will give to KSB all reasonable assistance
(excluding financial assistance) that KSB may require in connection with such proceedings and shall not communicate with any third party or make any statement or omission regarding liability in respect of any such legal proceedings.

  

	15.	PATENT 

  

	15.1	KSB hereby warrants that, to its best knowledge, the marketing, promotion, distribution, sales and/or Sub-license of the Product in the Territory will not constitute any
infringement of any patent owned by any third party. In the event that a claim of patent infringement is made against SOSEI, its Affiliate or Sub-Licensee by a third party in the Territory by reason of the commercial activity of SOSEI, its Affiliate
or Sub-Licensee hereunder, KSB shall indemnify and hold SOSEI, its Affiliate and Sub-licensee and their respective employees, directors, officers, agents and consultants from and against any suits, claims, liabilities, losses, expenses (including
legal expenses) and damages arising from such patent infringement. 

  

	15.2	SOSEI shall promptly notify KSB of any infringement known to it of any of the KSB Patents by third party in the Territory, which infringement bears adversely upon the SOSEI’s
exclusive enjoyment of its rights provided hereunder, and shall provide KSB with any available evidence of such infringement. 

  

	15.3	Upon reasonable notice of infringement pursuant to Clause 15.2, KSB shall have the opportunity to bring any suit or action for such infringement. If KSB is successful in abating the
infringement, then any amount recovered, whether by judgement, award, decree or settlement, shall first be applied to reimbursing to KSB the amount of expenses incurred by KSB in bringing such suit or action and the remainder, if any, shall be
divided appropriately between KSB and SOSEI with reference to the relative monetary injury suffered by each by reason of the past infringement. SOSEI shall, if requested by KSB and at the KSB’s expense, actively assist KSB in the prosecution of
such action. In the event that KSB fails or is unwilling for any reason to take action with respect to such infringement within a period of 6 (six) months following the SOSEI’s giving of notice thereof, SOSEI shall have the right to bring any
appropriate suit or action against the infringer at the expense of SOSEI. If SOSEI finds it necessary or desirable to join KSB as a party plaintiff, KSB shall execute all papers necessary or perform such other acts as may reasonably be required by
SOSEI. If SOSEI is successful in abating the infringement, then any amount recovered from the infringer, whether by judgement, award, decree or settlement, shall first be applied to reimbursing to SOSEI the amount of expenses incurred by SOSEI in
bringing such suit or action and the remainder, if any, shall be divided appropriately between KSB and SOSEI, with reference to the relative monetary injury suffered by each by reason of the past infringement. KSB shall, if requested by SOSEI and at
the expense of SOSEI, actively assist SOSEI in the prosecution of such action, including execution of all papers reasonably necessary and performance of such other action as may be reasonably required by SOSEI 

  

 18 

	15.4	KSB shall, at its expense, take reasonable measures to obtain and maintain all of the KSB Patent(s). 

  

	15.5	In the event that a third party would attack the validity of any KSB Patents in the Territory, then KSB shall at its own discretion promptly take such legal action as is required to
defend the validity of such KSB Patents and SOSEI shall give all reasonable assistance (excluding financial assistance) to KSB. SOSEI may be represented by counsel of its own selection at its own expense in any such legal action but KSB shall have
the right to control the suit and proceeding. 

  

	15.6	In the event that an exercise by SOSEI of the rights and licenses granted hereunder in the Territory would constitute an infringement of any patent right of third party, either
party shall, as soon as possible it becomes aware of the same, notify the other party thereof, giving in such notice full detail known to it of the patent right of such third party and extent of any alleged infringement. The parties shall then
discuss the situation and, if and to the extent necessary to permit SOSEI to practice the rights and licenses granted hereunder, shall use their reasonable efforts to obtain an appropriate license from such third party. The parties shall, in
negotiating such license with such third party, make every effort to minimize the royalties payable thereunder and, if such license requires SOSEI to pay royalties to such third party, the Royalties payable to KSB in the Territory shall be reduced
by an amount equal to those which SOSEI is required to pay to such third party. 

  

	16.	TERMINATION 

  

	16.1	This Agreement shall commence on the Effective Date and continue thereafter until the later date of (i) expiration of all KSB Patents or (ii) expiration of 10 (ten) years following
the first Launch Date, unless terminated by either party pursuant to any provision of this Agreement. 

  

	16.2	Upon the expiry of this Agreement, SOSEI shall thereafter have a full paid irrevocable perpetual license and right to market, promote and distribute sell and/or Sub-license the
Product throughout the Territory. 

  

	16.3	Either party (as the case may be) (“the Non Defaulting Party”) will be entitled to terminate this Agreement forthwith by notice in writing if: 

  

	 	16.3.1 	the other party (“the Defaulting Party”) commits a material breach of its obligations under this Agreement which (if capable of remedy) is not remedied within 60 (sixty)
days of written notice requiring it to be remedied being received by the Defaulting Party; or 

  

	 	16.3.2 	 the Defaulting Party becomes unable to pay its debts as they become due in the ordinary course of business or goes into either compulsory or voluntary liquidation
(except for the purposes of reconstruction or amalgamation previously notified to and approved by the Non-Defaulting Party (such approval not to be unreasonably withheld or delayed)) or a receiver or 

  

 19 

	 	 
administrator receiver is appointed in respect of the whole or any part of its assets or it is the subject of any petition for the appointment of an
administrator or if it makes or proposes any assignment or arrangement for the benefit of its creditors generally or shall otherwise become subject to or seek relief under any law relating to insolvency in any jurisdiction relevant to the Defaulting
Party. 

  

	16.4	SOSEI may terminate this Agreement by service of 3 (three) months’ notice in writing to KSB at any time during the term of this Agreement. 

  

	17.	CONSEQUENCES OF TERMINATION 

  

	17.1	In the event of termination by KSB of this Agreement under Clauses 16.3, SOSEI shall forthwith as at the effective date of termination: 

  

	 	17.1.1 	return to KSB the Dossier, all Clinical Data and any other documents, materials, data or information received from KSB hereunder and within its possession or Control containing or
evidencing any Intellectual Property of KSB and all Confidential Information of KSB; and 

  

	 	17.1.2 	subject only to Clause 17.4, cease all exploitation and marketing of the Product provided always that SOSEI shall be entitled to continue to sell the Product for a period of 6 (six)
calendar months thereafter in order to fulfil existing orders only (subject always to payment of the Royalties) and provided that SOSEI shall not sell such stock in a manner detrimental to the market for the Product in the Territory;

  

	 	17.1.3 	give or procure for KSB access to all data filed in connection with the Marketing Authorisations for the Product in the Territory; 

  

	 	17.1.4 	allow KSB to cross-reference the file relating to the Product held by the Regulatory Authority for the purpose of transferring the Marketing Authorisation for the Product in the
Territory to KSB or such other, person as it may then nominate; 

  

	 	17.1.5 	subject to SOSEI’s right to sell its stocks of the Products pursuant to Clause 17.1.2, transfer the adverse event database for the Product in the Territory to KSB;

  

	 	17.1.6 	take such action and execute such agreements and instruments as may be reasonably required by KSB to transfer the Trademark to KSB for a nominal consideration; and

  

	 	17.1.7 	 in the event of termination during the course of any Clinical Trials, use at the expense of KSB all reasonable endeavours to effect an orderly transfer to KSB (or
such other person as it may then direct) of the management and conduct of such Clinical Tridals, and continue at the expense of KSB to effect such 

  

 20 

	 	 
Clinical Trials for and on behalf of KSB until such time as such orderly transfer can be effected and SOSEI acknowledges that in the event of such
termination it shall not be entitled to any reimbursement or repayment of any sums paid to KSB under the terms of this Agreement prior to the effective date of termination, subject to the provision of Clause 17.2. 

  

	17.2	In the event of termination by SOSEI of this Agreement pursuant to Clause 16.4 due to reason that the marketing approval is not obtained by KSB with respect to the first Indication
of the Product in at least one major territory consisting of USA and the member countries of the EU prior to the date of filing an application for obtaining the Marketing Authorization in the Territory, KSB shall promptly return to SOSEI 50% (fifty
percent) of the milestone payments already paid to KSB before the effective date of such termination of this Agreement 

  

	17.3	In the event of termination by SOSEI of this Agreement pursuant to Clause 16.3 or pursuant to Clause 16.4 due to reason that the marketing approval is not obtained by KSB with
respect to the first Indication of the Product in at least one major territory consisting of USA and EU Union prior to the date of filing an application for obtaining the Marketing Authorization of the Product in the Territory and if KSB wishes to
utilize any Clinical Data and/or any other test or study data conducted by SOSEI and provided to KSB hereunder in any country of the world for any purpose whatsoever, SOSEI shall have the right to receive from KSB such compensation as shall be
agreed in writing between the parties. 

  

	17.4	Notwithstanding termination of this Agreement, pending transfer of the Marketing Authorisation of the Product to KSB (or such other person as it may then direct), SOSEI shall at
KSB’s request take such action as may be reasonably required by KSB at the expense of KSB to ensure that supplies to patients within the Territory being treated with the Product are not interrupted. 

  

	17.5	Termination or expiry of this Agreement for any cause shall not bring to an end: 

  

	 	17.5.1 	SOSEI’s obligation to pay the Royalties (whether before or after termination) or other sums which have accrued to KSB up to and including the effective date of termination; or

  

	 	17.5.2 	Any provision of this Agreement which in order for full effect to be given thereto needs to survive termination of this Agreement, and (for the avoidance of doubt) the provisions of
Clauses 13, 23 and 24 shall continue in full force and effect in accordance with their terms. 

  

	17.6	In the event of any termination of this Agreement by KSB, KSB may at its option confirm the continuation of any Sub-licences in order that such Sub-licences may continue in
accordance with their terms provided always that KSB shall not be under any continuing liability to perform any obligations of SOSEI contained in any such Sub-licence to the extent that the. performance of any such obligations might require the
provision of personnel or otherwise expenditure by KSB. 

  

 21 

	18.	ENTIRE AGREEMENT 

  

	18.1	Save for the Confidentiality Agreement dated April 11, 2001 between the parties, this Agreement shall constitute the entire agreement between the parties in relation to its subject
matter. Each party acknowledges that in entering into this Agreement it does not do so on the basis of and does not rely on any representation, warranty, or other provision except as expressly provided in this Agreement and all conditions,
warranties and other terms implied by statute or common law are hereby excluded to the fullest extent permitted by law Provided that nothing in this Agreement should be construed as limiting or excluding liability for fraud.

  

	18.2	The Agreement may be executed in more than one counterpart and shall come into force once each party has executed a counterpart in identical form and exchanged it with the other
party. 

  

	19.	ASSIGNMENT/SUBLICENSING 

  

	19.1	Neither Party shall assign, charge or transfer this Agreement to a third party without the written consent of the other, which consent shall not unreasonably be withheld or delayed
provided always that either party may assign or transfer this Agreement (in whole but not in part) to any Affiliate without obtaining the prior consent of the other provided that the performance by its Affiliate of its obligations hereunder is
guaranteed by the assignor and the assignor gives prior written notice to the other of such assignment. 

  

	20.	STATUS 

  

	20.1	Neither party is authorised to act as the agent of the other for any purpose whatsoever and neither party shall on behalf of the other enter into, or make, or purport to enter into
or make or represent that it has any authority to enter into or make any representation or warranty. 

  

	20.2	Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between the parties and neither of the parties shall do or suffer to be done anything whereby
it might be represented as a partner of the other party. 

  

	20.3	Each of the parties shall bear its own cost and expenses incidental to the preparation, negotiation and execution of this Agreement. 

  

	21.	AMENDMENT AND WAIVER 

  

	21.1	Any agreement to amend, vary or modify the terms of this Agreement in any manner shall be valid only if the amendment, variation or modification is effected in writing and signed by
duly authorised representatives of each of the parties hereto. 

  

	21.2	No delay by either party in enforcing any of the provisions of this Agreement shall be deemed a waiver of that party’s right subsequently to enforce such provision.

  

 22 

	22.	SEVERANCE 

  

	22.1	If any term or provision of any part thereof contained herein shall be declared or become unenforceable invalid or illegal in any respect under the law of any relevant jurisdiction:

  

	 	22.1.1 	such term or provision or part thereof shall be deemed to have been severed from the remaining terms of this Agreement and the terms and conditions hereof shall remain in full force
and effect as if this Agreement had been executed without the offending provision appearing herein; and 

  

	 	22.1.2 	the parties shall endeavour to agree an amendment which to the fullest extent possible will give lawful effect to their intentions as expressed in any term or provision severed
under Clause 22.1. 

  

	23.	NOTICES 

  

	23.1	Any notice required to be given under this Agreement shall be in writing and delivered by hand and/or sent by airmail post or by courier or facsimile (in the case of facsimile to be
confirmed in writing within two Business Days of being sent by such notice being delivered or sent by hand, airmail post or courier as aforesaid). The address for service of each party shall be as follows: 

  
 KSB: 
  
 KS Biomedix Holdings plc 
 1 Occam Court 
 Surrey Research Park 
 Guildford 
 Surrey GU2 7QY 
 England 
  
 Attn: Chief Executive Officer 
 Fax no (44)
1483 307 500 
  
 SOSEI: 
  
 4F Kojimachi NK Bldg., 
 2-14-3, Kojimachi, Chiyoda-ku, Tokyo 
 Japan

  
 Attn: Chief Executive Officer 
 Fax No: 81-35210-3291 
  

	23.2	A notice shall be deemed to have been served as follows: 

  

	 	23.2.1 	if delivered by hand, at the time of delivery; 

  

 23 

	 	23.2.2 	If delivered by courier, the expiration of 2 (two) Business Days after the envelope containing the same was delivered into the custody of the courier service;

  

	 	23.2.3 	if posted by airmail, at the expiration of 5 (five) Business Days after the envelope containing the same was delivered into the custody of the postal authorities;

  

	 	23.2.4 	if sent by facsimile and transmission is automatically acknowledged, at the expiration of 2 (two) hours after the same was despatched; 

  
 except that if a notice or other communication would be deemed to be
delivered under the above provisions on a day that is not a Business Day in the country of receipt or after 5.00 pm in that country, then it shall be deemed instead to have been delivered at 9.00 am on the next Business Day in that country.

  

	23.3	In proving service of any notice, it shall be sufficient to show that delivery by hand was made, or in the case of postal or courier delivery, that the envelope containing the
communication was properly addressed and delivered into the custody of the postal authorities as a prepaid airmail letter or into the custody of the courier as a prepaid courier package or, in the case of a facsimile, by production of a confirmatory
transmission report. 

  

	24.	FORCE MAJEURE 

  

	24.1	In the event that the performance of the obligations of either party is prevented, restricted or hindered by any event of Force Majeure such party: 

  

	 	24.1.1 	shall not be liable to the other party for any damages arising from any breach of the terms of this Agreement caused by Force Majeure; and 

  

	 	24.1.2 	shall immediately serve notice in writing on the other party specifying the nature of the Force Majeure, their effect upon its performance of this Agreement and the period of time
in which they are anticipated to apply; and 

  

	 	24.1.3 	shall use its reasonable endeavours to overcome the Force Majeure and resume its proper performance of its obligations under this Agreement. 

  

	24.2	If the circumstances referred to in Clause 24.1 prevail for a continuous period in excess of 3 (three) months, the party notified of such circumstances may, without prejudice to any
other rights or remedies which may be available to it, terminate this Agreement with immediate effect by giving written notice of termination to the other. In the event of any such termination by either party the provisions of Clause 17.1 shall
apply. 

  

 24 

	25.	THIRD PARTY RIGHTS 

  

	25.1	A person who is not a party to this Agreement has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement but this does not affect any
right or remedy of a third party which exists or is available apart from that Act. 

  

	26.	DISPUTE RESOLUTION 

  

	26.1	Within 7 (seven) Business Days of either party becoming aware of any dispute relating in any manner to this Agreement or the terms hereof it shall prepare and submit to the Chief
Executive Officer or such other senior manager as may be nominated from time to time for such purpose (“CEOs”) of each of the parties a memorandum or statement setting out its position in respect of the matter in dispute and its reasons
for adopting that position. The other party shall within 7 (seven) Business Days of receipt of the memorandum or statement prepare and submit to the other party a memorandum or statement setting out like particulars on its own behalf and the CEOs
shall consider the dispute in the light of those statements. 

  

	26.2	If the CEOs agree upon the resolution of the dispute they shall issue a joint statement setting out the agreed terms and shall exercise and powers available to them to procure that
the agreed terms are fully and promptly carried into effect. 

  

	26.3	If the dispute is not resolved or disposed of in accordance with this Clause 26, within 30 (thirty) days of compliance with the terms of Clause 26.1, or if either party shall fail
to comply with the terms of Clause 26.2, either party may proceed by notice in writing request mediation in accordance with the provisions of Clause 26.4. 

  

	26.4	If either party by notice in writing under Clause 26.3 invokes mediation, the CEOs shall agree upon a mediator within USA. Each party shall propose a list of up to 5 (five) names
within 10 (ten) Business Days of the date of the written notice invoking mediation. Each such name proposed shall be of an independent third party with appropriate experience and expertise. If any of the names are the same the parties shall agree
upon a mediator from the names they have jointly proposed. If none of the names are the same the party who initiates mediation shall select a mediator from the list provided by the non-initiating party. All lists of mediators shall include a full
resumé for each mediator named on the list. The parties shall complete the process of selecting a mediator within 15 (fifteen) Business Days of the date of the written notice invoking mediation. If the parties are unable to reach a mediated
resolution within 30 (thirty) Business Days after selection of the mediator, the provisions of Clause 27.2 shall apply. 

  

	27.	LAW AND JURISDICTION 

  

	27.1	Any controversy or claim of whatsoever nature arising out of or relating in any manner whatsoever to this Agreement or any breach of any terms of this Agreement shall be governed by
and construed in all respects in accordance with the laws of England. 

  

 25 

	27.2	Each party hereby irrevocably acknowledges and agrees that the Courts of Japan shall have non-exclusive jurisdiction to resolve any controversy or claim of whatsoever nature arising
out of or relating in any manner to this Agreement any terms of this Agreement or any breach of this Agreement or any such terms. 

  
 AS WITNESS the duly authorised representatives of each of the parties the day and year first before written. 
  

					
	 SIGNED by
 for and on behalf
of
 KS Biomedix Holdings PLC
	 	 )        
 )        
 )        

			
	/s/	 	 	 	 
	 By
	 	 	 	 

  

					
	 SIGNED by
 for and on behalf
of
 Sosei Co., Ltd.
	 	 )        
 )        
 )        

			
	/s/	 	 Kenzo Nakajima
	 	 
	 By
	 	 Kenzo Nakajima
 Executive VP and COO
	 	 

  

 26 

 SCHEDULE I 
  

SUPPLY AGREEMENT 
  

	1.	Procedure for forecasts and ordering. Extent to which forecasts became binding on the parties. 

  

	2.	Procedure for acceptance of orders, manufacture and delivery. 

  

	3.	Packaging and labelling requirements. 

  

	4.	If manufactured outside EU, Procedures for import and batch release in EU under authority of Marketing Authorisation holder. 

  

	5.	Pricing and payment terms. 

  
 Product to be supplied at a price calculated as the cost of manufacture plus a reasonable profit mark up, such price to be * of the Net Sales of the
Product sold by SOSEI, its Affiliate or Sub-licensee in the Territory. 
  

	6.	Termination. 

  
 Supply Agreement to continue for Term (as defined in Agreement)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]